

10582184.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTADK01625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS	3	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS	4	APR 02	DWPI: New display format ALLSTR available
NEWS	5	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS	6	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS	7	APR 07	CA/CAPLUS CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS	8	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAPLUS
NEWS	9	APR 07	MEDLINE Coverage Is Extended Back to 1947
NEWS	10	JUN 16	WPI First View (File WPIFV) will no longer be available after July 30, 2010
NEWS	11	JUN 18	DWPI: New coverage - French Granted Patents
NEWS	12	JUN 18	CAS and FIZ Karlsruhe announce plans for a new STN platform
NEWS	13	JUN 18	IPC codes have been added to the INSPEC backfile (1969-2009)
NEWS	14	JUN 21	Removal of Pre-IPC 8 data fields streamline displays in CA/CAPLUS, CASREACT, and MARPAT
NEWS	15	JUN 21	Access an additional 1.8 million records exclusively enhanced with 1.9 million CAS Registry Numbers -- EMBASE Classic on STN
NEWS	16	JUN 28	Introducing "CAS Chemistry Research Report": 40 Years of Biofuel Research Reveal China Now Atop U.S. in Patenting and Commercialization of Bioethanol
NEWS	17	JUN 29	Enhanced Batch Search Options in DGENE, USGENE, and PCTGEN
NEWS	18	JUL 19	Enhancement of citation information in INPADOC databases provides new, more efficient competitor analyses
NEWS	19	JUL 26	CAS coverage of global patent authorities has expanded to 61 with the addition of Costa Rica
NEWS	20	SEP 15	MEDLINE Cited References provide additional relevant records with no additional searching.

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,  
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

10582184.trn

NEWS LOGIN      Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:57:44 ON 27 SEP 2010

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

FILE 'REGISTRY' ENTERED AT 11:00:25 ON 27 SEP 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 SEP 2010 HIGHEST RN 1242846-81-6

DICTIONARY FILE UPDATES: 26 SEP 2010 HIGHEST RN 1242846-81-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10582184-1.str

10582184.trn



```
chain nodes :
10 11 13 16 20 21
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
12 14 15
chain bonds :
10-11 11-12 13-14 13-15 16-20 16-21
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 7-8 8-9 10-11 11-12 13-14 13-15 16-20 16-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
```

G1:[\*1],[\*2]

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 20:CLASS 21:CLASS
22:Atom
Generic attributes :
16:
Saturation          : Unsaturated
Type of Ring System : Monocyclic
```




L1 STRUCTURE UPLOADED

10582184.trn

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 [01],[02]

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:00:48 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 21063 TO ITERATE

100.0% PROCESSED 21063 ITERATIONS

25 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 412568 TO 429952


PROJECTED ANSWERS: 200 TO 800

L2 25 SEA SSS SAM L1

=> d scan

10582184.trn


L2 25 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN 3-Pyridinecarboxamide,  
1-cyclopropyl-5-(4-fluorophenyl)-N-[3-fluoro-4-(1H-  
pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,4-dihydro-4-oxo-  
MF C28 H20 F2 N4 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 25 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN  
IN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[[2-  
hydroxyethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-  
MF C27 H24 F N5 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10582184.trn

=> d his

(FILE 'HOME' ENTERED AT 10:57:44 ON 27 SEP 2010)

FILE 'REGISTRY' ENTERED AT 11:00:25 ON 27 SEP 2010

L1 STRUCTURE UPLOADED

L2 25 S L1

=> s l1 full

FULL SEARCH INITIATED 11:01:10 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 422397 TO ITERATE

100.0% PROCESSED 422397 ITERATIONS

457 ANSWERS

SEARCH TIME: 00.00.02

L3 457 SEA SSS FUL L1

=> file caplus

FILE 'CAPLUS' ENTERED AT 11:01:16 ON 27 SEP 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Sep 2010 VOL 153 ISS 14

FILE LAST UPDATED: 26 Sep 2010 (20100926/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 35 L3

=> d cbib abs hitstr 1-


YOU HAVE REQUESTED DATA FROM 35 ANSWERS - CONTINUE? Y/(N):y

10582184.trn

10582184.trn


L4 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2010:1040663 Document No. 153:334023 Preparation of araindole derivatives  
as  
inhibitors of the Abl and Src protein kinases. Yasri, Abdelaziz; Cheve, Gwenaeel; Bories, Cedric; Delon, Louis (Nova Decision, Fr.; Azasynth). PCT Int. Appl. WO 2010092489 A1 20100819, 129pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SM, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2010-1B593 20100212. PRIORITY: FR 2009-631 20090212; US 2009-202279P 20090212.

GI




AB The invention is related to the preparation of azaindoles I [R = NHCOR1, NH2 and derivs.; R1 = (un)substituted Ph, heteroaryl, arylalkyl, etc.; R2 = alkoxy, carbonyl, CONH2 and derivs., heterocyclylcarbonyl, etc.] as inhibitors of the Abl and Src protein kinases and to their pharmaceutical compns. Thus, hydrogenation of 5-nitro-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid Me ester over Pd/C, reaction of the amine with 2-bromobenzoyl chloride, saponification of 5-(2-bromobenzoylamino)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid Me ester and coupling of the acid with [3-(dimethylamino)propyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxamide (II). Azaindole II inhibited Abl and c-Src protein kinases in vitro with IC50 = 3.9+10-7 M and 2.2+10-6 M, resp. and selectively inhibited the proliferation of K562 cells over U397 cells.  
IT 1240322-34-2P, 5-[[4-(Methylcarbamoyl)phenyl]amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid methyl ester  
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of azaindoles as inhibitors of Abl and Src protein kinases)  
RN 1240322-34-2 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxylic acid, 5-[[4-[(methylamino)carbonyl]phenyl]amino]-, methyl ester (CA INDEX NAME)

L4 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




L4 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2010:1035754 Document No. 153:304354 Action assays and screening for HGFR inhibitors. Obaishi, Hiroshi; Nakagawa, Satoyuki; Toyama, Osamu; Kadowaki, Masashi; Uezugi, Mai; Watanabe, Keisuke (Elsai R & D Management Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2010178651 A 20100819, 49pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 2009-23936 20090204.

GI



AB Action assays and screening for HGFR inhibitors are offered by determination of the amount of mRNA expressions of c-Met, uPA, IL 8, VEGF, LIF, etc. with Northern blot, RT-PCR, microarray, RIA, ELISA, Western blot, etc. methods. The HGFR inhibitors include aminopyridinylphenylcyclopropane dicarboxamide analogs (I; Markush's structures given) and their effects on mRNA expression were tested in human stomach and lung cancer cell line.  
IT 1240049-76-6  
RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(action assays and screening for HGFR inhibitors)  
RN 1240049-76-6 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[3-fluoro-4-[[2-[[2-(1-piperidinyl)ethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)

L4 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)







10582184.trn

L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2010:913892 Document No. 153:2326130 Preparation of heterocyclic  
 apoptosis-inducing agents for treatment of cancer and immune disorders.  
 Kunzer, Aaron R.; Elmore, Steven W.; Hexamer, Laura; Park, Cheol-Min;  
 Souers, Andrew J.; Sullivan, Gerard M.; Wang, Gary T.; Wang, Xilu; Wendt,  
 Michael D. (Abbott Laboratories, USA). PCT Int. Appl. WO 2010083442 A1  
 20100722, 175pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ,  
 BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK,  
 DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GM, GT, HN, HR, HU, ID,  
 IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LB, LS, LT, LU,  
 LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,  
 PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH,  
 TJ; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA,  
 GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SM, SN, TD,  
 TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2010-US21245  
 20100115. PRIORITY: US 2009-145611P 20090119.

GI



I




II

AB Disclosed are compds. of Formula I (wherein, in which A1 is furyl,  
 imidazolyl, isothiazolyl, etc.; Z1 is (un)fused phenylene or  
 heteroarylene; Z2 is (un)fused phenylene, heteroarylene, cycloalkylene,  
 etc.; Z1A and Z2A are both absent or are taken together to form CH2,  
 CH2CH2, etc.; L1 is SO2NH, CONH, etc.; and Z3 is (un)fused Ph,  
 heteroaryl,  
 cycloalkyl, etc.), which inhibit the activity of anti-apoptotic Bcl-2  
 proteins, compns. containing the compds. and their use in treating  
 diseases  
 during which anti-apoptotic Bcl-2 protein is expressed. Synthetic  
 procedures for preparing I are exemplified. Example compound II was  
 prepared in  
 a multistep synthesis that culminated in the reaction of intermediates  
 4-[4-(cyclohexylmethyl)-4-methoxypiperidin-1-yl]benzoic acid and  
 (R)-5-[4-(dimethylamino)-1-(phenylthio)butan-2-ylamino]-4-nitrothiophene-2-


L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 sulfonamide. II had a Ki of 0.051449  $\mu$ M in a TR-FRET assay that  
 measured inhibition of a Bak BH3 peptide probe binding to Bcl-2 protein.  
 IT 1235865-74-3P 1235865-80-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (drug candidate; preparation of heterocyclic apoptosis-inducing  
 agents that  
 act as Bcl-2 protein inhibitors for treatment of cancer and immune  
 disorders)  
 RN 1235865-74-3 CAPLUS  
 CN 4-Morpholinecarboxylic acid, 2-[[[5-[[[4-[2-(4-chlorophenyl)-4,4-  
 dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-2-(1H-pyrrolo[2,3-  
 b]pyridin-5-yloxy]benzoyl]amino]sulfonyl]-4-methyl-2-thiazolyl]oxy]methyl]-  
 , 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)  
 Absolute stereochemistry.

PAGE 1-A




L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 1235865-80-1 CAPLUS  
 CN Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-  
 yl]methyl]-1-piperazinyl]-N-[[2-[[4-fluorotetrahydro-2H-pyran-4-  
 yl]methoxy]-4-methyl-5-thiazolyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-  
 yloxy)- (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A



10582184.trn


L4 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2010:877825 Document No. 153:1748540 Preparation of  
 tetrahydridipyrrolopyrrole derivatives for use as protein kinase signal  
 transduction modulators. Jones, Christopher Charles Victor; Huck, Bayard  
 R.; Sutton, Amanda E.; Askew, Benny C., Jr.; Brugger, Nadia; Smith, Garry  
 R. (Merck Patent GmbH, Germany). PCT Int. Appl. WO 2010080253 A1  
 20100715, 110pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ,  
 BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK,  
 DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID,  
 IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU,  
 LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE,  
 PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,  
 TM, RW, AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA,  
 GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SM, SN, TD,  
 TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2009-US6534  
 20091203. PRIORITY: US 2008-203022P 20081218.

GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [R1 = H, halo, CN, alkyl, etc.; Y = H, halo, aryl,  
 heteroaryl, etc.], and their pharmaceutically acceptable salts, are  
 prepared  
 and disclosed as protein kinase signal transduction modulators. Thus,  
 e.g., II was prepared by amination of  
 4-chloro-6,7,8,9-tetrahydro-5H-dipyrrolo[2,3-b;3',4'-d]pyrrole with  
 N-(4-aminophenyl)benzamide. Select I were evaluated in Src assays (data  
 given).  
 IT 1234702-26-1P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of tetrahydridipyrrolopyrrole derivs. for use as protein  
 kinase  
 signal transduction modulators)  
 RN 1234702-26-1 CAPLUS  
 CN Benzamide, N-[4-[(6,7,8,9-tetrahydro-5H-pyrrolo[3',4':4,5]pyrrolo[2,3-  
 b]pyridin-4-yl)amino]phenyl]- (CA INDEX NAME)


L4 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1234703-10-6 CAPLUS  
 CN Benzamide,  
 N-methyl-2-[(6,7,8,9-tetrahydro-5H-pyrrolo[3',4':4,5]pyrrolo[2,3-  
 b]pyridin-4-yl)amino]- (CA INDEX NAME)



L4 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 1234702-27-2P 1234702-40-9P 1234703-10-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of tetrahydridipyrrolopyrrole derivs. for use as protein  
 kinase  
 signal transduction modulators)  
 RN 1234702-27-2 CAPLUS  
 CN Benzamide, N-[4-[(6-acetyl-6,7,8,9-tetrahydro-5H-  
 pyrrolo[3',4':4,5]pyrrolo[2,3-b]pyridin-4-yl)amino]phenyl]- (CA INDEX  
 NAME)



RN 1234702-40-9 CAPLUS  
 CN Benzamide, N-[4-[(6-(3-chlorobenzoyl)-6,7,8,9-tetrahydro-5H-  
 pyrrolo[3',4':4,5]pyrrolo[2,3-b]pyridin-4-yl)amino]phenyl]- (CA INDEX  
 NAME)

L4 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2010:720942 Document No. 153:622950 Benzamide-sulfonamide derivatives as  
 apoptosis-inducing agents and their preparation, pharmaceutical  
 compositions and use in the treatment of cancer and immune and autoimmune  
 diseases. Bruncko, Milan; Dai, Yujia; Ding, Hong; Doherty, George A.;  
 Elmore, Steven W.; Hasvold, Lisa; Hexamer, Laura; Kunzer, Aaron R.;  
 Mantel, Robert A.; McClellan, William J.; Park, Chang H.; Park,  
 Cheol-Min;  
 Petros, Andrew M.; Song, Xiaohong; Souers, Andrew J.; Sullivan, Gerard  
 M.;  
 Tao, Zhi-Fu; Wang, Gary T.; Wang, Le; Wang, Xilu; Wendt, Michael D.  
 (Abbott Laboratories, USA). PCT Int. Appl. WO 2010065824 A2 20100610,  
 619pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB,  
 BG,  
 BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ,  
 EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS,  
 JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,  
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL,  
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, RW, AT,  
 BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE,  
 IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SM, SN, TD, TG, TR.  
 (English). CODEN: PIXXD2. APPLICATION: WO 2009-US66722 20091204.  
 PRIORITY: US 2008-119844P 20081204.

GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to benzamide-sulfonamide derivs. of formula I and  
 their pharmaceutically acceptable salts, prodrugs and salts of prodrugs.  
 The invention also relates to compns. containing the compds. of formula  
 I and  
 methods of treating diseases during which is expressed anti-apoptotic  
 Bcl-2 protein. Compds. of formula I can inhibit the activity of  
 anti-apoptotic Bcl-2 proteins. Compds. of formula I wherein A1 is N and  
 (un)substituted CH; B1, D1 and E1 are independently H, R1, OR1, SOO-2R1,  
 COR1, COOR1, OCOR1, NHR1, N(R1)2, CONHR1, CON(R1)2, NHCOR1, NR1COR1,  
 etc.;  
 Y1 is H, CN, NO2, COOH, halo, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17,  
 COR17, COOR17, SR17, SO2R17, etc.; E1Y1, Y1B1, B1A1 or A1D1 may taken  
 together with the atom attached to form benzene, naphthalene,  
 heteroarene,  
 (hetero)cycloalkane and (hetero)cycloalkene; R1 is R2-R5; R1a is  
 cycloalkyl, cycloalkenyl and cycloalkynyl; R2 and R3 are independently  
 (hetero)aryl, (un)fused benzene, (un)fused heteroarene and  
 (hetero)cycloalkane; R4 is (un)fused (hetero)cycloalkyl and (un)fused  
 (hetero)cycloalkenyl; R5 is (un)substituted alkyl, (un)substituted  
 alkenyl  
 and (un)substituted alkynyl; R17 is (un)fused benzene, (un)fused  
 heteroarene, (hetero)cycloalkane, (hetero)cycloalkene, etc.; Z1, Z2 and  
 Z3  
 are independently (un)fused phenylene, (un)fused heteroarylene,  
 (hetero)cycloalkane, (hetero)cycloalkene, etc.; Z1a and Z2a are both  
 absent or are taken together to form CH2, CH2CH2 and 2- to 6-membered  
 (hetero)alkylene; L1 is R37, OR37, SOO-2R37, COR37, COOR37, OCOR37,  
 OOCOR37, NHR37, etc.; R37 is a bond, (un)substituted alkylene,  
 (un)substituted alkenylene, etc.; and their pharmaceutically acceptable  
 salts, prodrugs and salts of prodrugs thereof, are claimed. Example


10582184.trn

L4 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 compd. II was prepd. starting from Et 2,4-difluorobenzoate and  
 2-methyl-5-indolol by using a multi-step procedure (procedure given).  
 All the invention compds. were evaluated for their Bcl-2 anti-apoptotic  
 activity. From the assay, it was detd. that II exhibited the Ki value of  
 0.000827  $\mu$ M.  
 IT 1228942-19-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (drug candidate; preparation of benzamide-sulfonamide derivs. as  
 apoptosis-inducing agents useful in the treatment of cancer and immune  
 and autoimmune diseases)  
 RN 1228942-19-5 CAPLUS  
 CN Benzamide, 4-[4-[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-  
 yl)methyl]-1-piperazinyl]-2-[(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-  
 N-[[3-nitro-4-[[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-  
 (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2010:503786 Document No. 152:4771470 Preparation of heterocyclic compounds  
 as protein kinase inhibitors. Kim, Tae-Seong; Lee, Eunhyung; Kim,  
 Doyoung; Park, Bu-Mahn; Park, Jiyeon; Joo, Jungje (NeoPharm Co., Ltd., S.  
 Korea). PCT Int. Appl. WO 2010044543 A2 20100422, 103pp. DESIGNATED  
 STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY,  
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,  
 FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,  
 KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW,  
 MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC,  
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN; RW: AT, BE, BF, BJ, CF,  
 CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC,  
 ML, MR, MT, NE, NL, NO, PT, SE, SM, SN, TD, TG, TR. (Korean). CODEN:  
 FIXXD2. APPLICATION: WO 2009-KR4830 20090828. PRIORITY: KR 2008-100522  
 20081014.  
 GI




AB Title compds. I [R1 = alkyl, cycloalkyl, arylalkyl, etc.; R2 =  
 (un)substituted alkyl; R3 = alkyl, cycloalkyl, arylalkyl, etc.; ; Q =  
 fused unsatd. heterocyclyl comprising 5-membered nitrogenous unsatd.  
 heterocycle and 6-membered nitrogenous unsatd. heterocycle; X = H or  
 halo;  
 Y = CH or N; Z = CH or N] or pharmaceutically acceptable salts or  
 stereoisomers thereof were prepared For example, Pd2dba3-catalyzed  
 coupling  
 reaction of 4-chloro-2-phenyl-1-(2-(trimethylsilylethoxymethyl)-1H-  
 pyrrolo[2,3-b]pyridine (preparation given) with tert-Bu  
 (3-fluoro-4-hydroxyphenyl)carbamate followed by deprotection using HCl,  
 treatment with NaOH, and HATU-mediated acylation with  
 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid  
 afforded compound II [R = H]. In c-Met luciferase assays, compound II  
 [R = F]  
 showed the IC50 value of 0.008 M. Compds. I are claimed useful for the  
 treatment of cancer, asthma, etc.

L4 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A



L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 IT 1221713-88-7P 1221713-90-1P 1221713-92-3P  
 1221714-34-6P 1221714-35-7P 1221714-36-8P  
 1221714-37-9P 1221714-38-0P 1221714-39-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of heterocyclic compds. as protein kinase inhibitors)  
 RN 1221713-88-7 CAPLUS  
 CN 1H-Pyrazole-4-carboxamide, N-[3-fluoro-4-[(2-phenyl-1H-pyrrolo[2,3-  
 b]pyridin-4-yl)oxy]phenyl]-2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl- (CA  
 INDEX NAME)




RN 1221713-90-1 CAPLUS  
 CN 1H-Pyrazole-4-carboxamide,  
 2-(4-fluorophenyl)-N-[[3-fluoro-4-[(2-phenyl-1H-  
 pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dihydro-1,5-dimethyl-3-oxo-  
 (CA INDEX NAME)


10582184.trn

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 1221713-92-3 CAPLUS  
CN 1H-Pyrazole-4-carboxamide,  
2-(4-fluorophenyl)-N-[3-fluoro-4-[(3-phenyl-1H-  
pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dihydro-1,5-dimethyl-3-oxo-  
(CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 1221714-34-6 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, 2-(4-fluorophenyl)-N-[3-fluoro-4-[(2-(2-  
thienyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dihydro-1,5-  
dimethyl-3-oxo- (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 1221714-35-7 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, 2-(4-fluorophenyl)-N-[3-fluoro-4-[(2-(3-  
thienyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dihydro-1,5-  
dimethyl-3-oxo- (CA INDEX NAME)

L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 1221714-36-8 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-[3-fluoro-4-[(2-(4-methoxyphenyl)-1H-  
pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2-(4-fluorophenyl)-2,3-dihydro-1,5-  
dimethyl-3-oxo- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1221714-37-9 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-[3-fluoro-4-[[2-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl- (CA INDEX NAME)



L4 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
RN 1221714-39-1 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-[3-fluoro-4-[[2-(2-thienyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl- (CA  
INDEX NAME)




```

IT      1221714-49-3P
        RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
        (Reactant or reagent)
        (preparation of heterocyclic compds. as protein kinase inhibitors)
RN      1221714-49-3 CAPLUS
CN      Carbamic acid, N-[3-fluoro-4-[[2-phenyl-1-[[2-
        (trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-,
        1,1-dimethylethyl ester (CA INDEX NAME)

```




RN 1221714-38-0 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-[3-fluoro-4-[[2-(3-thienyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl- (CA INDEX NAME)




10582184.trn

L4 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2010:494042 Document No. 153:76673 Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.  
 Williams,  
 David K.; Chen, Xiao-Tao; Tarby, Christine; Kaltenbach, Robert; Cai, Zhen-Wei; Tokarski, John S.; An, Yongmi; Sack, John S.; Wautlet, Barri; Gullo-Brown, Johnni; Henley, Benjamin J.; Jeyaseelan, Robert; Kellar, Kristen; Manne, Veeraswamy; Trainor, George L.; Lombardo, Louis J.; Fargnoli, Joseph; Borzilleri, Robert M. (Bristol-Myers Squibb Research and Development, Princeton, NJ, 08543-4000, USA). Bioorganic & Medicinal Chemistry Letters, 20(9), 2998-3002 (English) 2010. CODEN: BMCLE8.  
 ISSN: 0960-894X. Publisher: Elsevier B.V..  
 GI



AB Aminopyridinyloxy- or azaindolyloxy phenylamino heteroarylcarboxamides such as I are prepared and tested for their inhibition of Met kinase and for their inhibition of a human gastric cancer cell line. X-ray crystallog. of an aminopyridinyloxyphenylamino pyridinecarboxamide bound to Met kinase reveals that these compds. adopt a bioactive conformation, in the kinase domain, consistent with that seen for a 2-pyridone-based Met kinase inhibitor. I demonstrated potent in vivo antitumor activity in the GTL-16 human tumor xenograft model; its selectivity against various kinases is determined.  
 IT 888719-03-7  
 RI: PKP (Properties)  
 (crystal structure of an azaindolyloxyphenyl fluorophenylpyridinecarboxamide bound to Met kinase and comparison to the structure of an aminopyridinyloxyphenylamino pyridinecarboxamide bound to Met kinase)  
 RN 888719-03-7 CAPLUS  
 CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)


L4 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2010:479026 Document No. 152:4769780 Preparation of heteroarenes as receptor tyrosine kinase inhibitors.. Xi, Ning (USA). U.S. Pat. Appl. Publ. US 2010093727 A1 20100415, 8 pp. (English). CODEN: USXXCO. APPLICATION: US 2009-576375 20091009. PRIORITY: US 2008-105414P 20081014.  
 GI




10582184.trn

L4 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 1221442-62-1 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide,  
4-[4-[[[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)carbonyl]amino]-2-fluorophenoxy]-N-methyl-N-4-oxaspiro[2.4]hept-6-yl-  
(CA INDEX NAME)

L4 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




L4 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1221442-65-4 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-[4-[[[2-(4-azaspiro[2.5]oct-7-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-2-(4-fluorophenyl)-2,3-dihydro-1,5-dimethyl-3-oxo-  
(CA INDEX NAME)

L4 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2010:439254 Document No. 152:4222780 Methods for the treatment of cancer.  
Johns, Terrance (Ludwig Institute for Cancer Research, USA). PCT Int. Appl. WO 2010039248 A1 20100408, 139pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TW, UA, UB, UG, UZ, VC, VE, VN, YU, ZA, ZM, ZW. CLASS: A61K 31/00, A61P 35/00, A61P 37/00, A61P 39/00, A61P 41/00, A61P 43/00, A61P 47/00, A61P 49/00, A61P 51/00, A61P 53/00, A61P 55/00, A61P 57/00, A61P 59/00, A61P 61/00, A61P 63/00, A61P 65/00, A61P 67/00, A61P 69/00, A61P 71/00, A61P 73/00, A61P 75/00, A61P 77/00, A61P 79/00, A61P 81/00, A61P 83/00, A61P 85/00, A61P 87/00, A61P 89/00, A61P 91/00, A61P 93/00, A61P 95/00, A61P 97/00, A61P 99/00. CODEN: PIXXD2. APPLICATION: WO 2009-US5421 20090930. PRIORITY: US 2008-101971P 20081001.  
AB Methods for treating cancer with at least one HGF-Met inhibitor and at least one EGFR inhibitor are provided.  
IT 913377-52-3  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(methods for treatment of cancer)  
RN 913377-52-3 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-2,3-dihydro-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2-phenyl-  
(CA INDEX NAME)


PAGE 1-A



10582184.trn

L4 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 2-A




L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2009:1435911 Document No. 151:5651120 Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer. Burgess, Theresa L.; Coxon, Angela; Dussault, Isabelle; Kaplan-Lefko, Paula; Polverino, Anthony J.; Beaupre, Darrin (Amgen Inc., USA). PCT Int. Appl. WO 2009140549 A1 20091119, 83pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2009-US44034 20090514. PRIORITY: US 2008-127753P 20080514.  
AB This invention is in the field of pharmaceutical agents and specifically relates to compds., compns., uses and methods for treating cancer, by combining VEGF(R) inhibitors and inhibitors of HGF/SF:c-Met. E.g., enhanced activity was observed when AMG 706 (Motesanib) was combined with Amgen Compound 3 [N-[4-[4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamido)-2-fluorophenoxy]pyridin-2-yl]morpholine-4-carboxamide] compared to either single agent alone when tested on human gastric adenocarcinoma cancer cells.  
IT 913377-52-3, N-[3-Fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxamide  
RI: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combinations VEGF(R) inhibitors and hepatocyte growth factor inhibitors for cancer treatment)  
RN 913377-52-3 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2,3-dihydro-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2-phenyl- (CA INDEX NAME)

L4 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



PAGE 1-A



PAGE 2-A



L4 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2009:296108 Document No. 150:3066710 Preparation of amino substituted pyrimidine, pyrrolopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis. Gray, Nathanael; Sim, Taebo; Choi, Hwan Guen (Dana Farber Cancer Institute, USA). PCT Int. Appl. WO 2009032694 A1 20090312, 109pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2008-US74472 20080827. PRIORITY: US 2007-966449P 20070828.  
GI



AB This invention relates to novel amino substituted pyrimidine compds., pharmaceutical compns. containing such compds. and the use of those compds. or compns. for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients. Compds. of formula I [Z = N or CH; A = (un)substituted aryl or heteroaryl; B = (un)substituted Ph when Z = N; or B = (un)substituted Ph, pyrazolyl or thiazolyl when Z = CH; Y = SO2, SO2NH, NH-SO2, etc.; X independently = NH,



10582184.trn

L4 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
O or S; R1 = H, alkyl, halo-alkyl, cycloalkyl, etc.; R2 = H, alkyl, halo-alkyl, cycloalkyl, etc.; R3 = substituted piperidinyl, pyrrolidinyl, morpholinyl, etc.; Ra = H; Rb = halo; or Ra and Rb, taken together with the atoms to which they are bound form a pyrazolo ring fused to the pyrimidine ring when Z = N or a pyrrolo ring fused to the pyrimidine ring when Z = CH], and their physiolo. acceptable salts, solvates, hydrates or stereoisomers, are prepd. Thus, e.g., II was prepd. by condensation reaction of 1-(4-amino-3-methoxyphenyl)piperidin-4-ol with 6-chloro-N-[2-(isopropylsulfonyl)phenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine which was prepd. in 6 steps from 1-fluoro-2-nitrobenzene and 2-propanethiol. Selected invention compds. are inhibitors of NFM-ALK dependent cellular proliferation with EC50 of  $\leq 1 \mu\text{M}$  in cell proliferation assays.


IT 1125594-12-8P, (1,4'-Bipiperidin-1'-yl)[4-[[[2-(isopropylsulfonyl)phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]-3-methoxyphenyl]methanone

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of amino substituted pyrimidine, pyrrolopyridine and pyrazolopyrimidine derivs. useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis)

RN 1125594-12-8 CAPLUS

CN Methanone, [1,4'-bipiperidin]-1'-yl[3-methoxy-4-[[[4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2009:291628 Document No. 150:2830290 Preparation of 2-(Het)arylamino-6-aminopyridine derivatives and fused forms thereof as kinase inhibitors for treating hyperproliferative and angiogenesis disorders. Gray, Nathanael S.; Michellys, Pierre-Yves; Pei, Wei; Marsilje, Thomas H.; Lu, Wenshuo; Chen, Bei; Uno, Tetsuo; Jin, Yunho; Jiang, Tao (IRM LLC, Bermuda). PCT Int. Appl. WO 2009032703 A1 20090312, 110pp. DESIGNATED STATES: W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, MT, NE, NL, NO, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2008-US74490 20080827. PRIORITY: US 2007-966449P 20070828.



AB This invention relates to novel amino substituted pyrimidine compds. of formula I (wherein A and B are (un)substituted aryl or (un)substituted heteroaryl; Y is SO2, SO2NH, NHSO2, etc.; X is NH, O or S; Z is N or CH; R1 and R2 are independently H, C1-C6 alkyl, halo-(C1-C6alkyl), etc.; R3 is (un)substituted piperidine, (un)substituted pyrrolidine, etc.; Ra is H and

L4 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
Rb is halo, or together with the atoms to which they are bound form a pyrazolo or a pyrrolo ring fused to the pyridine/pyrimidine ring), pharmaceutical compds. contg. such compds. and the use of those compds.

or compns. for treating hyperproliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients. I act as kinase inhibitors to control the hyperproliferative and angiogenesis disorders. Synthetic procedures for prep. I are exemplified. Example compd. II was prepd. by a multistep synthesis culminating in the reaction of the appropriate [1H-pyrrolo[2,3-b]pyridin-6-ylamino]nicotinic acid

with 1-methyl-4-(piperidin-4-yl)piperazine. Many of the invention compds. tested inhibited NFM-ALK-dependent cellular proliferation with EC50 values of  $\leq 1 \mu\text{M}$ .


IT 1125594-12-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2-(Het)arylamino-6-aminopyridine derivs. and fused forms thereof as kinase inhibitors for treating hyperproliferative and angiogenesis disorders)

RN 1125594-12-8 CAPLUS

CN Methanone, [1,4'-bipiperidin]-1'-yl[3-methoxy-4-[[[4-[[2-[(1-methylethyl)sulfonyl]phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]phenyl]- (CA INDEX NAME)



L4 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2009:184429 Document No. 150:3213550 Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily. Schroeder, Gretchen M.; An, Yongming; Cai, Zhen-Wei; Chen, Xiao-Tao; Clark, Cheryl; Cornelius, Lyndon A. M.; Dai, Jun; Gullo-Brown, Johnni; Gupta, Ashok; Henley, Benjamin; Hunt, John T.; Jeyaseelan, Robert; Kamath, Amrita; Kim, Kyoung; Lippy, Jonathan; Lombardo, Louis J.; Manne, Veeraswamy; Oppenheimer, Simone; Sack, John S.; Schmidt, Robert J.; Shen, Guoxiang; Stefanski, Kevin; Tokarski, John S.; Trainor, George L.; Wautlet, Barri S.; Wei, Donna; Williams, David K.; Zhang, Yingru; Zhang, Yueping; Fargnoli, Joseph; Borzilleri, Robert M. (Bristol-Myers Squibb Research and Development, Princeton, NJ, 08543-4000, USA). Journal of Medicinal Chemistry, 52(5), 1251-1254 (English) 2009. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 150:321355. Publisher: American Chemical Society.

AB Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were identified as potent and selective Met kinase inhibitors. Substitution of the pyridine 3-position gave improved enzyme potency, while substitution of the pyridone 4-position led to improved aqueous solubility and kinase selectivity.

Analog 10 demonstrated complete tumor stasis in a Met-dependent GTL-16 human gastric carcinoma xenograft model following oral administration. Because of its excellent in vivo efficacy and favorable pharmacokinetic and preclin. safety profiles, 10 has been advanced into phase I clin. trials.

IT 888719-03-7

RL: RCT (Reactant); RACT (Reactant or reagent)


(aminopyridinyloxy-Fluorophenyl oxo-dihydropyridine-carboxamides preparation and Met kinases inhibition)

RN 888719-03-7 CAPLUS

CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)

10582184.trn

L4 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




L4 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

2009;8400 Document No. 150:2375570 Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors. Schirok, Hartmut;

Kast, Raimund; Figueroa-Perez, Santiago; Bennabi, Samir; Gnoth, Mark J.; Feurer, Achim; Heckroth, Heike; Thutewohl, Michael; Paulsen, Holger; Knorr, Andreas; Huetter, Joachim; Lobell, Mario; Muentner, Klaus; Geiss, Volker; Ehme, Heimo; Lang, Dieter; Radtke, Martin; Mittendorf, Joachim; Stasch, Johannes-Peter (Medicinal Chemistry, Bayer HealthCare AG, Wuppertal, 42096, Germany). ChemMedChem, 3(12), 1893-1904 (English)

2008 CODEN: CHEMGX. ISSN: 1860-7179. OTHER SOURCES: CASREACT 150:237557. Publisher: Wiley-VCH Verlag GmbH & Co. KGaA.

GI



AB Rho kinase plays a pivotal role in several cellular processes such as vasoregulation, making it a suitable target for the treatment of hypertension and related disorders. We discovered a compound class of Rho

kinase (ROCK) inhibitors containing a 7-azaindole hinge-binding scaffold tethered to an aminopyrimidine core. Herein we describe the structure-activity relationships elucidated through biochem. and functional assays. The introduction of suitable substituents at the 3-position of the bicyclic moiety led to an increase in activity, which was required to design compds. with favorable pharmacokinetic profile. Azaindole I was identified as a highly selective and orally available

ROCK inhibitor able to cause a sustained blood pressure reduction in vivo.


IT 855863-43-3P 855863-45-5P 867017-94-5P  
867017-95-6P 867017-96-7P 867017-98-9P  
867018-08-4P 867018-09-5P 885327-74-2P  
1115491-48-9P 1115491-51-4P 1115491-54-7P  
1115491-79-6P 1115491-82-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of amino(pyrimidinylamino)phenoxyazaindoles using etherification and substitution as key steps and their Rho kinase inhibitory activity)

RN 855863-43-3 CAPLUS


CN Acetamide, N-[4-[[3-bromo-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-

L4 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
b]pyridin-4-yl]oxy]-3-fluorophenyl]- (CA INDEX NAME)




RN 855863-45-5 CAPLUS

CN Acetamide, N-[3-fluoro-4-[[3-methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)



RN 867017-94-5 CAPLUS


CN Acetamide, N-[4-[[3-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3,5-difluorophenyl]- (CA INDEX NAME)



L4 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 867017-95-6 CAPLUS

CN Acetamide, N-[4-[[3-bromo-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3,5-difluorophenyl]- (CA INDEX NAME)



RN 867017-96-7 CAPLUS

CN Acetamide, N-[3,5-difluoro-4-[[3-methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 867017-98-9 CAPLUS


CN Acetamide, N-[4-[[3-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]- (CA INDEX NAME)

10582184.trn

L4 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 867018-08-4 CAPLUS  
CN Acetamide, N-[4-([3-ethenyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]- (CA INDEX NAME)




RN 867018-09-5 CAPLUS  
CN Acetamide, N-[4-([3-ethyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]- (CA INDEX NAME)


L4 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1115491-51-4 CAPLUS  
CN Acetamide, N-[3,5-difluoro-4-([1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 1115491-54-7 CAPLUS  
CN Acetamide, N-[4-([3-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3,5-difluorophenyl]- (CA INDEX NAME)



L4 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 885327-74-2 CAPLUS  
CN Acetamide, N-[3-fluoro-4-([1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 1115491-48-9 CAPLUS  
CN Acetamide, N-[4-([3-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]- (CA INDEX NAME)

L4 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 1115491-79-6 CAPLUS  
CN Acetamide, N-[3,5-difluoro-4-([1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 1115491-82-1 CAPLUS  
CN Acetamide, N-[4-([3-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3,5-difluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)



10582184.trn

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2008;966421 Document No. 149;3230460 Discovery of Pyrrolopyridine-Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities. Kim, Kyoung Soon; Zhang, Liping; Schmidt, Robert; Cai, Zhen-Wei; Wei, Donna; Williams, David K.; Lombardo, Louis J.; Trainor, George L.; Xie, Dianlin; Zhang, Yaquan; An, Yongmi; Sack, John S.; Tokarski, John S.; Darienzo, Celia; Kamath, Amrita; Marathe, Punit; Zhang, Yueping; Lippy, Jonathan; Jeyaseelan, Robert; Wautlet, Barri; Henley, Benjamin; Gullo-Brown, Johnni; Manne, Veeraswamy; Hunt, John T.; Fagnoli, Joseph; Borzilleri, Robert M. (Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research and Development, Princeton, NJ, 08543-4000, USA). Journal of Medicinal Chemistry, 51(17), 5330-5341 (English) 2008. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 149;323046.

Publisher:

American Chemical Society.

AB Conformationally constrained 2-pyridone analog 2 is a potent Met kinase inhibitor with an IC50 value of 1.8 nM. Further SAR of the 2-pyridone based inhibitors of Met kinase led to potent 4-pyridone and pyridine N-oxide inhibitors such as 3 and 4. The X-ray crystallog. data of the inhibitor 2 bound to the ATP binding site of Met kinase protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogs was rationalized. Many of these analogs showed potent antiproliferative activities against the Met dependent GTL-16 gastric carcinoma cell line. Compound 2 also inhibited Flt-3 and VEGFR-2 kinases with IC50 values of 4 and 27 nM, resp. It possesses a favorable pharmacokinetic profile in mice and demonstrates significant in vivo antitumor activity in the GTL-16 human gastric carcinoma xenograft model.

IT 888719-03-7P


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrrolopyridine-pyridone-based inhibitors of Met kinase: preparation, crystallog. anal., and activities)

RN 888719-03-7 CAPLUS

CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 1052114-93-8P


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(pyrrolopyridine-pyridone-based inhibitors of Met kinase: preparation, crystallog. anal., and activities)

RN 1052114-93-8 CAPLUS

CN 4H-Pyran-3-carboxamide, 5-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-4-oxo- (CA INDEX NAME)

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT 888719-01-5P

888719-05-9P

888719-07-1P

888719-09-3P

888719-16-2P

888719-18-4P

888719-68-4P

888855-00-3P

1052114-76-7P

1052114-77-8P

1052114-78-9P

1052114-79-0P

1052114-87-0P

1052114-90-5P

1052114-94-9P

1052114-95-0P

1052114-96-1P

1052114-97-2P


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrrolopyridine-pyridone-based inhibitors of Met kinase: preparation, crystallog. anal., and activities)

RN 888719-01-5 CAPLUS


CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-oxide (CA INDEX NAME)

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-05-9 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-phenyl-, 1-oxide (CA INDEX NAME)




RN 888719-07-1 CAPLUS


CN 2-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-phenyl- (CA INDEX NAME)

10582184.trn

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-09-3 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-1-phenyl- (CA INDEX NAME)




RN 888719-16-2 CAPLUS  
CN [1(2H),3'-Bipyridine]-3-carboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo- (CA INDEX NAME)

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888855-00-3 CAPLUS  
CN 3-Pyridinecarboxamide, 1-[(4-fluorophenyl)methyl]-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 1052114-76-7 CAPLUS  
CN 3-Pyridinecarboxamide, 5-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-18-4 CAPLUS  
CN [1(2H),2'-Bipyridine]-3-carboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo- (CA INDEX NAME)




RN 888719-68-4 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-1-(3-methylbutyl)-2-oxo- (CA INDEX NAME)

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1052114-77-8 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(1,1-dimethylethyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)



RN 1052114-78-9 CAPLUS  
CN 3-Pyridinecarboxamide, 1-cyclopropyl-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)


10582184.trn

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1052114-79-0 CAPLUS  
CN 3-Pyridinecarboxamide, 1-[4-(aminocarbonyl)phenyl]-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,4-dihydro-2-oxo- (CA INDEX NAME)


PAGE 1-A



L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1052114-94-9 CAPLUS  
CN 3-Pyridinecarboxamide, 1-cyclopropyl-5-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 1052114-95-0 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(3-fluoro-4-methoxyphenyl)-5-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 1052114-87-0 CAPLUS  
CN 3-Pyridinecarboxamide, 5-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,4-dihydro-1-methyl-4-oxo- (CA INDEX NAME)




RN 1052114-90-5 CAPLUS  
CN 3-Pyridinecarboxamide, 5-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,4-dihydro-1-(2-hydroxyethyl)-4-oxo- (CA INDEX NAME)

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1052114-96-1 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-chloro-3-fluorophenyl)-5-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)



RN 1052114-97-2 CAPLUS

10582184.trn


L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)




IT 888854-97-5  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pyrrolopyridine-pyridone-based inhibitors of Met kinase: preparation, crystallog. anal., and activities)  
RN 888854-97-5 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



PAGE 1-A



PAGE 2-A




L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2008:668195 Document No. 149:1910310 Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors. Cai, Zhen-Wei; Wei, Donna; Schroeder, Gretchen M.; Cornelius, Lyndon A. M.; Kim, Kyoung; Chen, Xlao-Tao; Schmidt, Robert J.; Williams, David K.; Tokarski, John S.; An, Yongmi; Sack, John S.; Manne, Veeraswamy; Kamath, Amrita; Zhang, Yueping; Marathe, Punit; Hunt, John T.; Lombardo, Louis J.; Fargnoli, Joseph; Borzilleri, Robert M. (Research and Development, Bristol-Myers Squibb, Princeton, NJ, 08543-4000, USA). Bioorganic & Medicinal Chemistry Letters, 18(11), 3224-3229 (English) 2008. CODEN: BMCLE8. ISSN: 0960-894X. OTHER SOURCES: CASREACT 149:191031. Publisher: Elsevier Ltd.. GI



AB A series of acylurea analogs derived from pyrrolopyridine and aminopyridine scaffolds were identified as potent inhibitors of Met kinase activity. The SAR at various positions of the two kinase scaffolds was investigated. These studies led to the discovery of compds. (I) and (II), which demonstrated favorable pharmacokinetic properties in mice and significant antitumor activity in a human gastric carcinoma xenograft model.  
IT 888719-37-7P 888854-97-5P 888855-03-6P  
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
(discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors)  
RN 888719-37-7 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 888854-97-5 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888855-03-6 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




IT 888719-93-5P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors)  
RN 888719-93-5 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxylic acid,  
4-[2-fluoro-4-[[[2-(4-fluorophenyl)acetyl]amino]carbonyl]amino]phenoxy]-,  
methyl ester (CA INDEX NAME)

L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




IT 888717-80-4P 888719-26-4P 888719-30-0P  
888719-31-1P 888719-35-5P 888719-45-7P  
888719-94-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors)  
RN 888717-80-4 CAPLUS  
CN Propanediamide, N1-(4-fluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 888719-26-4 CAPLUS  
CN Benzeneacetamide, N-[[[4-[[3-[2-(dimethylamino)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]amino]carbonyl]-4-fluoro- (CA INDEX NAME)



L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-45-7 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide,  
4-[2-fluoro-4-[[[2-(4-fluorophenyl)acetyl]amino]carbonyl]amino]phenoxy]-N-  
[3-pyridinylmethyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-94-6 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




IT 888854-97-5D, complex with Met kinase  
RL: PRP (Properties)  
(discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors)  
RN 888854-97-5 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




IT 888719-44-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors)  
RN 888719-44-6 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(2,2,2-trichloroacetyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A





PAGE 2-A



10582184.trn


L4 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2008:619356 Document No. 148:5858830 Preparation of pyrrolopyridines as  
novel kinase inhibitors. Bhidre, Rajeev S.; Marinier, Anne (Bristol-Myers  
Squibb Company, USA). PCT Int. Appl. WO 2008060907 A2 20080522, 49pp.  
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR,  
BW,  
BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,  
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,  
KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN,  
MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC,  
SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, RW: AT, BE, BF,  
BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT,  
LU, MC, ML, MR, MT, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN:  
PIXXD2. APPLICATION: WO 2007-US83850 20071107. PRIORITY: US  
2006-865181P  
20061110.

GI




AB The title comps. I [X, Y = CH<sub>2</sub>, NH, S or O, or one of X and Y is absent;  
R1-R3 = H, alkyl, cycloalkyl, etc.; R4, R5 = H, alkyl, aryl, etc.; or  
NR4R5 = (un)substituted heterocyclyl ring; R6 = H, alkyl, aryl, etc.; and  
their pharmaceutically acceptable salts] which inhibit the tyrosine  
kinase  
activity of growth factor receptors such as VEGFR-2, FGFR-1 and IGFR-1,  
thereby making them useful as anti-cancer agents, were prepared E.g., a  
multi-step synthesis of II, starting from Et 6-aminonicotinate and  
phenylacetylene, was given. Comps. I were tested against various  
kinases. For example, II showed IC<sub>50</sub> of 16 nM against VEGFR2. Comps. I  
are also useful for the treatment of other diseases associated with  
signal

L4 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1027785-02-9 CAPLUS  
CN Benzamide,  
N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]-3-[(2-phenyl-1H-  
pyrrolo[2,3-b]pyridin-5-yl)thio]- (CA INDEX NAME)




L4 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
transduction pathways operating through growth factor receptors.  
IT 1027784-98-0P, N-[1-(4-Fluorophenylsulfonyl)piperidin-4-yl]-3-  
[(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide  
1027784-99-1P, N-[1-(4-Fluorophenylsulfonyl)azetidin-3-yl]-3-[(2-  
phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide 1027785-00-7P

N-[1-(4-Fluorophenylsulfonyl)azetidin-3-yl]-3-[(2-phenyl-1H-pyrrolo[2,3-  
b]pyridin-5-yl)thio]benzamide 1027785-02-9P,  
N-[1-(4-Fluorophenylsulfonyl)piperidin-4-yl]-3-[(2-phenyl-1H-pyrrolo[2,3-  
b]pyridin-5-yl)thio]benzamide  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(preparation of pyrrolopyridines as novel kinase inhibitors for  
producing a  
vascular permeability reducing effect)  
RN 1027784-98-0 CAPLUS  
CN Benzamide,  
N-[1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl]-3-[(2-phenyl-1H-  
pyrrolo[2,3-b]pyridin-5-yl)oxy]- (CA INDEX NAME)



RN 1027784-99-1 CAPLUS  
CN Benzamide, N-[1-[(4-fluorophenyl)sulfonyl]-3-azetidinyl]-3-[(2-phenyl-1H-  
pyrrolo[2,3-b]pyridin-5-yl)oxy]- (CA INDEX NAME)



RN 1027785-00-7 CAPLUS  
CN Benzamide, N-[1-[(4-fluorophenyl)sulfonyl]-3-azetidinyl]-3-[(2-phenyl-1H-  
pyrrolo[2,3-b]pyridin-5-yl)thio]- (CA INDEX NAME)

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2008:529117 Document No. 148:5176930 Preparation of novel  
pyrrolo[2,3-b]pyridine derivatives as histamine c-Met kinase inhibitors.  
Hamaajima, Toshihiro; Nakamura, Hiroko; Tang, Jun (Glaxo Group Limited,  
UK). PCT Int. Appl. WO 2008049855 A2 20080502, 75pp. DESIGNATED STATES:  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ,  
LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ,  
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK,  
SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ; RW: AT, BE, BF, BJ, CF, CG, CH,  
CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR,  
MT, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PAXXD2.  
APPLICATION: WO 2007-EP61412 20071024. PRIORITY: US 2006-863139P  
20061027.

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The invention relates to comps. of formula I, and processes for  
preparing  
them, comps. containing them and their use in treating diseases  
relating to  
inappropriate c-Met activity. Comps. with formula of I [R1 =  
(un)substituted aryl; R2 = H, COOR3, C(O)NR4R5 or (un)substituted aryl; X  
= NH or O; R3 and R4 independently = H or alkyl; R5 = alkyl-NR6R7,  
alkyl-SO2-alkyl, alkyl-OH, alkyl-C(O)NH2, alkylheteroaryl,  
(un)substituted  
alkylaryl or cycloalkyl; R6 and R7 independently = H, alkyl or together  
may form a 4- to 7-membered saturated heterocyclic ring] and their  
pharmaceutically acceptable salts or solvates, are prepared and  
disclosed as  
histamine c-Met kinase inhibitors. Thus, e.g., II was prepared in a  
multi-step synthesis starting from 4-chloro-3-pyridinecarboxaldehyde with  
1,1-dimethylethyl (4-hydroxyphenyl)carbamate. I were found to have IC<sub>50</sub>  
values at the c-Met receptor of ≥ 6.0 in cell-base assay, e.g., II  
showed IC<sub>50</sub> value of ranging from 4.5 to 5.5 (no unit). As histamine  
c-Met kinase inhibitors, I should prove useful for the treatment of c-Met  
related disorders in particular cancer, cardiovascular diseases, viral  
diseases, etc.

IT 1021950-21-9P 1021950-40-2P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of novel pyrrolo[2,3-b]pyridine derivs. as histamine  
c-Met  
kinase inhibitors)  
RN 1021950-21-3 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxylic acid,


4-[4-[[[1-[(4-fluorophenyl)amino]carbonyl]cyclopropyl]carbonyl]amino]phen  
oxy]- (CA INDEX NAME)

10582184.trn

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1021950-40-2 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxylic acid,  
4-[[4-[[[1-[(4-fluorophenyl)amino]carbonyl]cyclopropyl]carbonyl]amino]phe  
nyl]amino]-, ethyl ester (CA INDEX NAME)




IT 1021950-23-1P 1021950-24-2P 1021950-25-3P  
1021950-26-4P 1021950-27-5P 1021950-28-6P  
1021950-29-7P 1021950-30-0P 1021950-31-1P  
1021950-32-2P 1021950-33-3P 1021950-34-4P  
1021950-35-5P 1021950-36-6P 1021950-37-7P

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1021950-25-3 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[[2-[(1-  
piperazinyl)ethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-  
yl]oxy]phenyl]- (CA INDEX NAME)




RN 1021950-26-4 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[[2-[(4-  
morpholinyl)ethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-  
yl]oxy]phenyl]- (CA INDEX NAME)

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


1021950-39-9P 1021950-44-6P 1021950-46-8P  
1021950-47-9P 1021950-48-0P 1021950-49-1P  
1021950-55-9P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(prepn. of novel pyrrolo[2,3-b]pyridine derivs. as histamine c-Met  
kinase inhibitors)  
RN 1021950-23-1 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[[2-[[[2-  
(methylsulfonyl)ethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-  
yl]oxy]phenyl]- (CA INDEX NAME)



RN 1021950-24-2 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-[4-[[[2-[[[2-  
(dimethylamino)ethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-  
yl]oxy]phenyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)




RN 1021950-27-5 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-[4-[[[2-[[[3-  
(dimethylamino)propyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-  
yl]oxy]phenyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)




RN 1021950-28-6 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-[4-[[[2-[[[2-  
(dimethylamino)ethyl)methylamino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-  
yl]oxy]phenyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)

10582184.trn

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1021950-29-7 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[2-[[[(2-hydroxyethyl)amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 1021950-30-0 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-[4-[[2-[[[(2-amino-2-oxoethyl)amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1021950-33-3 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-[4-[[2-[[[(4-(dimethylamino)phenyl)methyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)




RN 1021950-34-4 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[2-[[[(2-methoxyphenyl)methyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1021950-31-1 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[2-[[[(2-imidazol-5-yl)ethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 1021950-32-2 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[2-[[[(2-hydroxy-4-methoxyphenyl)ethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1021950-35-5 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[2-[[[(2-methoxyphenyl)methyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 1021950-36-6 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-[4-[[2-[[[(3-[(dimethylamino)methyl]phenyl)amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)

10582184.trn

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1021950-37-7 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-((1H-pyrrolo[2,3-b]pyridin-4-yl)amino)phenyl]- (CA INDEX NAME)




RN 1021950-39-9 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-phenyl-N'-[4-((1H-pyrrolo[2,3-b]pyridin-4-yl)amino)phenyl]- (CA INDEX NAME)

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1021950-44-6 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-[4-[[2-[(cyclopropylamino)carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]amino]phenyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)




RN 1021950-46-8 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[2-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]amino]phenyl]- (CA INDEX NAME)

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1021950-47-9 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[2-[[[2-(1H-imidazol-5-yl)ethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]amino]phenyl]- (CA INDEX NAME)




RN 1021950-48-0 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[2-[[[2-(methylsulfonyl)ethyl]amino]carbonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]amino]phenyl]- (CA INDEX NAME)

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 1021950-49-1 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-yl]amino]phenyl]- (CA INDEX NAME)




RN 1021950-55-9 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxylic acid,

4-[4-[[[1-[[[4-fluorophenyl]amino]carbonyl]cyclopropyl]carbonyl]amino]phenoxy]-, ethyl ester (CA INDEX NAME)

10582184.trn

L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




IT 1021950-22-0P 1021950-38-8P 1021950-43-5P  
1021950-45-7P 1021950-54-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of novel pyrrolo[2,3-b]pyridine derivs. as histamine

c-Met kinase inhibitors)


RN 1021950-22-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxylic acid,  
4-[[4-[(1-carboxycyclopropyl)carbonyl]amino]phenoxy]-, 2-ethyl ester (CA  
INDEX NAME)




RN 1021950-38-8 CAPLUS


L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 1021950-54-8 CAPLUS  
CN Cyclopropanecarboxylic acid,  
1-[[[4-[(2-phenyl-1H-pyrrolo[2,3-b]pyridin-4-  
yl)amino]phenyl]amino]carbonyl]- (CA INDEX NAME)



L4 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
CN Cyclopropanecarboxylic acid, 1-[[[4-[(1H-pyrrolo[2,3-b]pyridin-4-  
ylamino]phenyl]amino]carbonyl]- (CA INDEX NAME)



RN 1021950-43-5 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxylic acid,  
4-[[4-[(1-carboxycyclopropyl)carbonyl]amino]phenyl]amino]-, 2-ethyl  
ester (CA INDEX NAME)




RN 1021950-45-7 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-2-carboxylic acid,  
4-[[4-[[[1-[(4-fluorophenyl)amino]carbonyl]cyclopropyl]carbonyl]amino]phe  
nyl]amino]- (CA INDEX NAME)

L4 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2007:643727 Document No. 147:726590 Preparation of pyrrolo[2,3-b]pyridines  
as inhibitors of kinases for the treatment of cancer. Dong, Han-Qing;  
Foreman, Kenneth; Li, An-Hu; Mulvihill, Mark Joseph; Panicker, Bijoy;  
Steinig, Arno G.; Stolz, Kathryn M.; Weng, Qinghua; Jin, Meizhong; Volk,  
Brian; Wang, Jing; Wang, Ti; Beard, James D. (Osi Pharmaceuticals, Inc.,  
USA). PCT Int. Appl. WO 2007067537 A1 20070614, 140pp. DESIGNATED  
STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,  
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ,  
LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ,  
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK,  
SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG; RW: AT, BE, BF, BJ, CF,  
CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC,  
ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.  
APPLICATION: WO 2006-US46391 20061205. PRIORITY: US 2005-748110P  
20051207; US 2006-860531P 20061122.


GI




I



II



III



IV

AB Pyrrolo[2,3-b]pyridines I [R = (un)substituted alkyl, alkoxyalkyl,  
alkoxyalkylcarbonyl, heterocyclylalkyl, alkylcarbonyl, heteroaryl, etc.;  
R1 = (un)substituted aryl, heteroaryl, heterocyclyl; R2 = R1Y; R3 = H,  
(un)substituted alkyl or alkoxyalkyl, halo, azido; R4 = H, alkyl, halo,  
cyano, (un)substituted alkylthio, aminoalkyl, amino, or alkoxyalkyl,  
etc.;  
X = 1,2,3,6-tetrahydro-1,4-pyridinediyl, (un)substituted  
1,4-piperidinediyl; Y = bond, (un)substituted amino, Me, aminoalkylamino,  
alkoxyalkylamino, or alkylaminocarbonylalkylamino, O, S, particularly  
arylamino- or aryloxy-substituted pyrrolo[2,3-  
b]pyridinyltetrahydropyridinecarboxylic acid esters or amides such as II

10582184.trn


L4 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 from (Boc = tert-butoxycarbonyl), are prep'd. as inhibitors of kinases for the treatment of cancer in animals or humans. II is prep'd. in five steps  
 with pyrrolopyridine III (prep'd. by a lit. procedure); desilylation of III  
 with sulfuric acid, phenylsulfonylation of the pyrrole nitrogen,  
 regioselective lithiation and iodination of the pyrrole (with some iodination of the phenylsulfonyl group), substitution with 1H-indazole-5-amine with concomitant desulfonylation, and Suzuki coupling of the heteroaryl bromide  
 with the dioxaborolanyl tetrahydropyridinecarboxylate IV provides II.  
 Some of the compds. of the invention such as II show 50% inhibition of at least

one of the following kinases (Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3 $\beta$ , EGFR, p70S6K, BMK, SGK, CaMKII, Tie-2, IGF-1R, Ron, Met, or KDR kinases) at a concn. of 30  $\mu$ M. The compds. can also be administered with other anticancer agents such as Avastin, Iressa, Tarceva, Erbitux, or cisplatin.

IT 940943-85-1P 940944-25-2P 940944-65-0P  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[2,3-b]pyridines, particularly arylamino- or aryloxy-substituted  
 pyrrolo[2,3-b]pyridinyl tetrahydropyridinecarboxylic acid esters or amides, as inhibitors of kinases for treatment of cancer)


RN 940943-85-1 CAPLUS  
 CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[3-(aminocarbonyl)phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 940944-25-2 CAPLUS  
 CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[[3-[(methylanino)carbonyl]phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

L4 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2007:619209 Document No. 147:726580 Preparation of pyrrolo[2,3-b]pyridines as inhibitors of kinases for the treatment of cancer. Dong, Han-Qing; Foreman, Kenneth; Li, An-Hu; Mulvihill, Mark Joseph; Panicker, Bijoy; Steinig, Arno G.; Stolz, Kathryn M.; Weng, Qinghua; Jin, Meizhong; Volk, Brian; Wang, Jing; Wang, Ti; Beard, James D. (OSI Pharmaceuticals, Inc., USA). U.S. Pat. Appl. Publ. US 20070129364 A1 20070607, 165 pp. (English). CODEN: USXXCO. APPLICATION: US 2006-634003 20061205. PRIORITY: US 2005-748110P 20051207.


GI




I



II



III




IV


AB Pyrrolo[2,3-b]pyridines I [R = (un)substituted alkyl, alkoxyalkyl, alkoxyalkylcarbonyl, heterocyclylalkyl, alkylcarbonyl, heteroaryl, etc.; R1 = (un)substituted aryl, heteroaryl, heterocyclyl; R2 = R1Y; R3 = H, (un)substituted alkyl or alkoxyalkyl, halo, azido; R4 = H, alkyl, halo, cyano, (un)substituted alkylthio, aminoalkyl, amino, or alkoxyalkyl, etc.;

X = 1,2,3,6-tetrahydro-1,4-pyridinediyl, (un)substituted 1,4-piperidinediyl; Y = bond, (un)substituted amino, Me, aminoalkylamino, alkoxyalkylamino, or alkylaminocarbonylalkylamino, O, S], particularly arylamino- or aryloxy-substituted pyrrolo[2,3-b]pyridinyl tetrahydropyridinecarboxylic acid esters or amides such as II (Boc = tert-butoxycarbonyl), are prepared as inhibitors of kinases for the treatment of cancer in animals or humans. II is prepared in five steps from pyrrolopyridine III (prepared by a lit. procedure); desilylation of III with sulfuric acid, phenylsulfonylation of the pyrrole nitrogen, regioselective

L4 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 940944-65-0 CAPLUS  
 CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[3-(aminocarbonyl)phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




L4 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 lithiation and iodination of the pyrrole (with some iodination of the phenylsulfonyl group), substitution with 1H-indazole-5-amine with concomitant desulfonylation, and Suzuki coupling of the heteroaryl bromide  
 with the dioxaborolanyl tetrahydropyridinecarboxylate IV provides II.  
 Some of the compds. of the invention such as II show 50% inhibition of at least

one of the following kinases (Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3 $\beta$ , EGFR, p70S6K, BMK, SGK, CaMKII, Tie-2, IGF-1R, Ron, Met, or KDR kinases) at a concn. of 30  $\mu$ M. The compds. can also be administered with other anticancer agents such as Avastin, Iressa, Tarceva, Erbitux, or cisplatin.

IT 940943-85-1P 940944-25-2P 940944-65-0P  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[2,3-b]pyridines, particularly arylamino- or aryloxy-substituted  
 pyrrolo[2,3-b]pyridinyl tetrahydropyridinecarboxylic acid esters or amides, as inhibitors of kinases for treatment of cancer)

RN 940943-85-1 CAPLUS  
 CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[[3-(aminocarbonyl)phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 940944-25-2 CAPLUS  
 CN 1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[4-[[3-[(methylanino)carbonyl]phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




10582184.trn

L4 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)





RN 940944-65-0 CAPLUS  
CN 1(2H)-Pyridinecarboxylic acid, 4-[[4-(aminocarbonyl)phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



L4 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2007:350589 Document No. 146:3588230 Preparation of  
pyrrolo[2,3-b]pyridinyloxy benzamide derivatives as Met kinase  
inhibitors.

Borzilleri, Robert M.; Cai, Zhen-Wei; Wei, Donna D.; Tokarski, John S. (Bristol-Myers Squibb Company, USA). PCT Int. Appl. WO 2007035428 A1 20070329, 52pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LB, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2006-US35885 20060914. PRIORITY: US 2005-717357P 20050915.

GI



AB Title compds. represented by the formula I & II [wherein R2 = independently H, halo, cyano, etc.; n = 1-3; X, W, M = independently -CR2 or N; R3, R6, R11 = independently H, (un)substituted (cyclo)alkyl, (hetero)aryl, etc.; V = N or -CR10; B = O, -NR11, S(m) or CR12R13; m = 0-2; R4, R5, R10 = independently H, halo(alkyl), NO2, etc.; R12, R13 = independently H, halo, (un)substituted (cyclo)alkyl (hetero)aryl, etc.; A = (un)substituted N containing heterocyclyl] were prepared as Met kinase inhibitors. For example, III was provided in a multi-step synthesis starting from the coupling reaction of 2-hydroxy-3-nitropyridine with


L4 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
4-fluorophenylboronic acid. The Met kinase assay for pharmacol. properties was described. The title compds. and their pharmaceutical compns. are useful as Met kinase inhibitors for the treatment of cancers (no data).

IT 930576-14-0P, 4-[(1H-Pyrrolo[2,3-b]pyridin-4-yl)oxy]-2,5-difluoro-N-[1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridin-3-yl]benzamide trifluoroacetate 930576-20-8P, 4-[(1H-Pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluoro-N-[1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridin-3-yl]benzamide trifluoroacetate  
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrrolo[2,3-b]pyridinyloxy benzamide derivs. as Met

kinase inhibitors)  
RN 930576-14-0 CAPLUS  
CN Benzamide, 2,5-difluoro-N-[1-(4-fluorophenyl)-1,2-dihydro-2-oxo-3-pyridinyl]-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 930576-13-9  
CMF C25 H15 F3 N4 O3



CM 2

CRN 76-05-1  
CMF C2 H F3 O2


L4 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 930576-20-8 CAPLUS  
CN Benzamide, 3-fluoro-N-[1-(4-fluorophenyl)-1,2-dihydro-2-oxo-3-pyridinyl]-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 930576-19-5  
CMF C25 H16 F2 N4 O3



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



10582184.trn

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2007:173336 Document No. 146:2293370 Preparation of urea derivatives as  
 multi kinase inhibitors. Ozawa, Sawako; Oikawa, Nobuhiro; Mizuguchi,  
 Eisaku; Ebike, Hirotsato; Watanabe, Fumio; Morikami, Kenji; Shimma,  
 Nobuo;  
 Izhi, Nobuya; Tsukaguchi, Toshiyuki; Tamaki, Yasuhiro; Takahashi,  
 Hidenori (Chugai Seiyaku Kabushiki Kaisha, Japan; The University of  
 Tokyo). PCT Int. Appl. WO 2007018137 A1 20070215, 15pp. DESIGNATED  
 STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,  
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
 GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA,  
 LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG,  
 NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM,  
 SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF,  
 CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC,  
 ML, MR, NE, NL, PT, SE, SN, TD, TG. (Japanese). CODEN: PIXXD2.  
 APPLICATION: WO 2006-JP315465 20060804. PRIORITY: JP 2005-228726  
 20050805; JP 2005-347532 20051201.


GI



AB The title comps. I [wherein Ar = (un)substituted Ph or naphthyl; T =  
 alkyl, alkoxy, etc.; X = O, CH2, CO, etc.; Y = CH or N; R2-R4 =  
 independently H, (un)substituted alkyl, etc.], or pharmaceutically  
 acceptable salts or prodrugs thereof are prepared as multi kinase  
 inhibitors. For example, the compound II was prepared in a multi-step  
 synthesis. Some of comps. I showed good inhibitory activities against  
 human cancer cell growth.


IT 924908-32-7P 924908-34-9P 924908-35-0P  
 924908-36-1P 924908-37-2P 924908-38-3P  
 924908-39-4P 924908-40-7P 924908-42-9P  
 924908-43-0P 924908-44-1P 924908-47-4P  
 924908-48-5P 924908-49-6P 924908-51-0P  
 924908-52-1P 924908-53-2P 924908-54-3P  
 924908-55-4P 924908-56-5P 924908-57-6P  
 924908-58-7P 924908-59-8P 924908-60-1P

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 CN Urea, N-[5-(2-methoxyethoxy)-2-naphthalenyl]-N'-[4-(1H-pyrrolo[2,3-  
 bipyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 924908-35-0 CAPLUS  
 CN Urea,  
 N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N'-[4-(tetrahydro-2H-  
 pyran-4-yl oxy)-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 924908-61-2P 924908-62-3P 924908-63-4P  
 924908-66-7P 924908-67-8P 924908-68-9P  
 924908-69-0P 924908-71-4P 924908-74-7P  
 924908-75-8P 924908-76-9P 924908-77-0P  
 924908-78-1P 924908-80-5P 924908-81-6P  
 924908-84-9P 924908-86-1P 924908-88-3P  
 924908-89-4P 924908-93-0P 924908-94-1P  
 924908-96-3P 924909-01-3P 924909-02-4P  
 RN: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (drug candidate; prepn. of urea derivs. as multi kinase inhibitors)  
 RN 924908-32-7 CAPLUS  
 CN Urea, N-[4-(2-methoxyethoxy)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-  
 pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 924908-34-9 CAPLUS

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A



RN 924908-36-1 CAPLUS  
 CN Urea,  
 N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N'-[3-[(tetrahydro-2H-  
 pyran-4-yl oxy)-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 924908-37-2 CAPLUS  
 CN Urea, N-[4-(3-fluoropropyl)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-  
 pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-38-3 CAPLUS  
CN Urea, N-[4-(3,3-difluoropropyl)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-39-4 CAPLUS  
CN Urea, N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N'-[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-40-7 CAPLUS  
CN Urea, N-[4-(2-fluoroethoxy)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 924908-42-9 CAPLUS  
CN Urea, N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N'-[4-(trifluoromethoxy)-3-(trifluoromethyl)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-43-0 CAPLUS  
CN Urea, N-[4-(2-fluoroethyl)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-44-1 CAPLUS  
CN Urea, N-[3-(2-fluoroethyl)-5-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 924908-47-4 CAPLUS  
CN Urea, N-[3-(3-fluoropropyl)-5-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 924908-49-6 CAPLUS  
CN Urea, N-[4-(4-fluorobutyl)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




RN 924908-48-5 CAPLUS  
CN Urea, N-[3-(3,3-difluoropropyl)-5-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 924908-51-0 CAPLUS  
CN Urea, N-[3-(4-fluorobutyl)-5-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 924908-52-1 CAPLUS  
CN Urea, N-[3-(4,4-difluorobutyl)-5-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 924908-53-2 CAPLUS  
CN Urea, N-[5-(2-fluoroethyl)-2-naphthalenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 924908-54-3 CAPLUS  
CN Urea, N-[5-(2,2-difluoroethyl)-2-naphthalenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 924908-55-4 CAPLUS  
CN Urea, N-[5-(3-fluoropropyl)-2-naphthalenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 924908-56-5 CAPLUS  
CN Urea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 924908-57-6 CAPLUS  
CN Urea, N-[4-(3-fluoro-3-methylbutyl)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


PAGE 1-A



10582184.trn


L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 924908-58-7 CAPLUS  
CN Urea, N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N'-[3-(trifluoromethyl)-4-(3,3,3-trifluoropropyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 924908-59-8 CAPLUS  
CN Urea, N-[4-ethyl-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-60-1 CAPLUS  
CN Urea, N-[4-ethenyl-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-61-2 CAPLUS  
CN Urea,  
N-[4-(fluoromethyl)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 924908-62-3 CAPLUS  
CN Urea,  
N-[4-[2-(1-methylethoxy)ethoxy]-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-63-4 CAPLUS  
CN Urea,  
N-[3-[2-(1-methylethoxy)ethoxy]-5-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 924908-67-8 CAPLUS  
CN Urea, N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N'-[3-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 924908-68-9 CAPLUS  
CN Urea, N-[3-(2,2-difluoroethoxy)-5-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

i-PrO-CH2-CH2-O-




RN 924908-66-7 CAPLUS  
CN Urea, N-[4-(2,2-difluoroethoxy)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

F2CH-CH2-O-



RN 924908-69-0 CAPLUS  
CN Urea, N-[4-(2,2-difluoroethyl)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


PAGE 1-A




10582184.trn

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 924908-71-4 CAPLUS  
CN Urea, N-[3-(2,2-difluoroethyl)-5-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 924908-74-7 CAPLUS  
CN Urea, N-[4-(4,4-difluorobutyl)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-75-8 CAPLUS  
CN Urea,  
N-[4-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-76-9 CAPLUS  
CN Urea, N-[4-(2-fluorophenoxy)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 924908-77-0 CAPLUS  
CN Urea, N-[4-(4-fluorophenoxy)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-78-1 CAPLUS  
CN Urea, N-[4-(3-fluorophenoxy)-3-(trifluoromethyl)phenyl]-N'-(4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-81-6 CAPLUS  
CN Urea,  
N-[3-[2-fluoro-1-(fluoromethyl)ethoxy]-5-(trifluoromethyl)phenyl]-N'-(4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-80-5 CAPLUS  
CN Urea,  
N-[4-[(3-fluorocyclohexyl)oxy]-3-(trifluoromethyl)phenyl]-N'-(4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 924908-84-9 CAPLUS  
CN Urea, N-[4-(2,2-difluoroethoxy)-3-(trifluoromethyl)phenyl]-N'-(4-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl)- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 924908-93-0 CAPLUS  
CN Urea,  
N'-[4-(4-fluorophenoxy)-3-(trifluoromethyl)phenyl]-N-methyl-N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924908-94-1 CAPLUS  
CN Urea,  
N-[4-(4-fluorophenoxy)-3-(trifluoromethyl)phenyl]-N-methyl-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 924908-96-3 CAPLUS  
CN Urea,  
N-[4-(3,3-difluoropropyl)-3-(trifluoromethyl)phenyl]-N-methyl-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 924909-01-3 CAPLUS  
CN Urea,  
N'-[4-(4-fluorophenoxy)-3-(trifluoromethyl)phenyl]-N-(methoxymethyl)-N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 924909-02-4 CAPLUS  
CN Urea,  
N-[4-(4-fluorophenoxy)-3-(trifluoromethyl)phenyl]-N-(methoxymethyl)-N'-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




IT 924909-64-8P 924909-65-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of urea derivs. as multi kinase inhibitors)  
 RN 924909-64-8 CAPLUS  
 CN Urea, N-[4-formyl-3-(trifluoromethyl)phenyl]-N'-[4-(1H-pyrrolo[2,3-  
 b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




L4 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 924909-65-9 CAPLUS  
 CN Urea, N-[4-(hydroxymethyl)-3-(trifluoromethyl)phenyl]-N'-[4-(1H-  
 pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2007:11341 Document No. 146:1219410 Pyrrolo[2,3-b]pyridine derivatives as  
 protein kinase inhibitors and their preparation, pharmaceutical  
 compositions and use in the treatment of diseases. Ibrahim, Prabha N.;  
 Artis, Dean R.; Bremer, Ryan; Habets, Gaston; Mamo, Shumeye; Nespi,  
 Marika; Zhang, Chao; Zhang, Jiazhong; Zhu, Yong-Liang; Zuckerman,  
 Rebecca;  
 West, Brian; Suzuki, Yoshihisa; Tsai, James; Hirth, Klaus-Peter; Bolla,  
 Gideon; Spevak, Wayne; Cho, Hanna; Gillette, Samuel J.; Wu, Guoxian; Zhu,  
 Hongyao; Shi, Shenghua (Plexxikon, Inc., USA). PCT Int. Appl. WO  
 2007002433 A1 20070104, 631 pp. DESIGNATED STATES: W: AE, AG, AL, AM,  
 AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE,  
 DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL,  
 IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,  
 LY, MA, MD, MG, MK, MN, MW, MX, NZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,  
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK,  
 ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,  
 TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2006-US24524  
 20060621. PRIORITY: US 2005-692960P 20050622; US 2005-731528P 20051028.


GI




AB Comps. of formula I which are active on protein kinases are described,  
 as well as methods of using such comps. to treat diseases and conditions  
 associated with aberrant activity of protein kinases. Comps. of  
 formula I  
 wherein Q is (un)substituted aryl, (un)substituted indole,  
 (un)substituted  
 heteroaryl, etc.; A is O, S, (un)substituted methylene, NH and derivs.,  
 CO, CS, SO and SO2; R4 - R6 is H, halo, (un)substituted lower alkyl,  
 (un)substituted lower alkenyl, (un)substituted alkynyl, (un)substituted  
 (hetero)cycloalkyl, and (un)substituted (hetero)aryl; and their  
 pharmaceutically acceptable salts, prodrugs, tautomers, and isomers  
 thereof, are claimed. Example compound II was prepared by carboxylation  
 of  
 2,4-difluoroaniline with benzyl chloroformate; the resulting benzyl  
 3-amino-2,6-difluorobenzoate underwent sulfonylation with  
 propane-1-sulfonyl chloride to give benzyl  
 2,6-difluoro-3-(propylsulfonylamino)benzoate, which underwent  
 hydrogenation to give the corresponding benzoic acid, which underwent  
 chlorination, to give the corresponding acid chloride, which underwent  
 reaction with 5-bromo-7-azaindole to give compound II. All the invention  
 comps. were evaluated for their protein kinase inhibitory activity.

10582184.trn



L4 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 Several of the tested compds. exhibited good protein kinase inhibitory activity against several kinases.  
 IT 918517-24-5P 918518-45-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of pyrrolopyridine derivs. as protein kinase inhibitors useful in treatment of diseases)  
 RN 918517-24-5 CAPLUS  
 CN Acetamide, N-[3-(1H-pyrrolo[2,3-b]pyridin-4-ylamino)phenyl]- (CA INDEX NAME)



RN 918518-45-3 CAPLUS  
 CN Acetamide, N-[3-(1H-pyrrolo[2,3-b]pyridin-5-ylamino)phenyl]- (CA INDEX NAME)




L4 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2006:1312063 Document No. 146:626950 Preparation of  $\alpha$ -carbolines as CDK1 inhibitors. Sennhenn, Peter; Mantoullidis, Andreas; Treu, Matthias; Tontsch-Grunt, Ulrike; Spevak, Walter; McConnell, Darryl; Schoop, Andreas;  
 Brueckner, Ralph; Jacobi, Albrecht; Guertler, Ulrich; Schnapp, Gisela; Klein, Christian; Himmelsbach, Frank; Pautsch, Alexander; Betzemeier, Bodo; Herfurth, Lars; Mack, Juergen; Wiedennayer, Dieter; Bader, Gerd; Reiser, Ulrich (Boehringer Ingelheim International GmbH, Germany);  
 Boehringer Ingelheim Pharma GmbH & Co. KG). PCT Int. Appl. WO 2006131552 A1 20061214, 158pp. DESIGNATED STATES: W; AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2. APPLICATION: WO 2006-EP63034 20060608. PRIORITY: EP 2005-105051 20050609; EP 2005-105052 20050609; EP 2005-105054 20050609.  
 GI




AB The invention is related to the preparation of  $\alpha$ -carbolines I [X = O, NR1, CHR1; R1 = H, halo/alkyl; R2, R3 = independently H, Ra, Rb or Ra substituted with  $\geq 1$  different Rb and/or Rc groups; Ra = independently at each occurrence cycloalkyl/cycloalkyl, aryl, 3-8 membered heterocyclyl, 5-10 membered heteroaryl, etc.; Rb = a distinct

L4 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 residue independently selected from OCF3, halo, CN, NO2, CO2H and derivs.,  
 SONH2 and derivs., etc.; Rc = independently selected from H, (un)substituted aryl/cyclo/alkyl, aryl, 4-14 membered heterocyclylalkyl, 6-16 membered heteroarylalkyl, etc.; R4 = NHC(Rc) or (un)substituted cyclo/alkyl, aryl, 3-8 membered heterocyclyl, etc.; R5 = independently at each occurrence H, halo, halo/alkyl, their tautomers, racemates, enantiomers, diastereomers and mixts., and their pharmaceutically usable salts, for the treatment of diseases characterized by excessive or abnormal cell proliferation and to their use for prepg. a pharmaceutical compn. Thus, reacting 9H-pyrido[2,3-b]indole with phosgene in MeOH in the presence of AlCl3, redn. of the Me ester, treatment with sodium benzenesulfinate, and nucleophilic substitution with N-methylpiperazine in N-methylpyrrolidone gave carboline II (no data for the first two steps). I inhibited proliferation of NCI-H460 non-small cell lung cancer cells (IC50 < 500 nM).  
 IT 916822-26-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of  $\alpha$ -carbolines as CDK1 inhibitors for treating cell proliferation disorders)  
 RN 916822-26-9 CAPLUS  
 CN Benzamide, 2-[[6-[(2-thienylsulfonyl)methyl]-9H-pyrido[2,3-b]indol-4-yl]amino]- (CA INDEX NAME)




L4 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2006:1252802 Document No. 146:278140 Pyrrolopyridines useful as inhibitors of protein kinase and their preparation, pharmaceutical compositions, and use in the treatment of various diseases. Ledebner, Mark W.; Wannamaker, Marion W.; Farmer, Luc J.; Wang, Tiansheng; Pierce, Albert C.; Martinez-Botella, Gabriel; Bethiel, Randy S.; Bemis, Guy M.; Wang, Jian; Salituro, Francesco G.; Arnott, Michael J.; Come, Jon H.; Green, Jeremy; Stewart, Michelle; Marhefka, Craig (Vertex Pharmaceuticals Incorporated, USA). PCT Int. Appl. WO 2006127587 A1 20061130, 201pp. DESIGNATED STATES: W; AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SH, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2006-US19711 20060522. PRIORITY: US 2005-683554P 20050520.  
 GI




AB The invention relates to compds. of formula I, which are useful as inhibitors of protein kinases, particularly of JAK family and ROCK family kinases. The invention also provides pharmaceutically acceptable compns. comprising said compds. and methods of using the compns. in the treatment of various disease, conditions, or disorders. Compds. of formula I wherein Q is a (un)substituted (un)saturated 3- to 8-membered (hetero)monocyclic ring and (un)saturated 8- to 12-membered (hetero)bicyclic ring; Z is a bond, NH, C1-3 alkylamine, and C=CH2; R1 and R2 are independently (un)substituted C1-2 alkyl; R3 is H, Cn, NO2, (un)substituted C1-6 aliphatic; and their pharmaceutically acceptable salts thereof are claimed. Example compound II was prepared by cross-coupling of 4-bromo-1-tosyl-1H-[2,3-b]pyridine with 3-dimethylaminophenylboronic acid derivative All the invention compds. were evaluated for their JAK and ROCK kinase inhibitory activity. From the kinase inhibition assay, it was determined that compound II exhibited Ki values of less than 0.5  $\mu$ M against JAK2, JAK3 and ROCK-I.  
 IT 916173-56-3P 916173-61-0P

10582184.trn

L4 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; prepn. of pyrrolopyridines as inhibitors of protein kinase useful in the treatment of various diseases)  
 RN 916173-56-3 CAPLUS  
 CN Propanamide,  
 N-[3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)amino]phenyl]-  
 (CA INDEX NAME)




RN 916173-61-0 CAPLUS  
 CN Benzanide, 3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)amino]-4-methyl-  
 (CA INDEX NAME)



L4 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2006:1147676 Document No. 145:4550090 Substituted cyclic amide derivatives as protein kinase inhibitors for treating hepatocyte growth factor (HGF)-related diseases. Kim, Tae-Seong; Bauer, David; Bellon, Steven; Boezio, Alessandro; Booker, Shon; Choquette, Deborah; D'Amico, Derin C.; D'Angelo, Noel; Dominguez, Celia; Fellows, Ingrid M.; Germain, Julie; Graceffa, Russell; Harmange, Jean-Christophe; Hirai, Satoko; La, Daniel; Lee, Matthew; Liu, Longbin; Norman, Mark H.; Potashman, Michele; Roveto, Philip; Siegmund, Aaron C.; Xi, Ning; Yang, Kevin (Amgen Inc., USA). PCT Int. Appl. WO 2006/116713 A1 20061102, 281pp. DESIGNATED STATES: W; AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2006-US16344 20060427. PRIORITY: US 2005-675805P 20050427.


GI



AB Selected compds. of general formula R-X-W-Y-R1 (wherein R = an aryl or heterocyclic ring or ring system; W = (un)substituted Ph, benzomorpholinyl, C3-7 cycloalkyl, etc.; X = O, S, S(O), SO2, etc.; Y = carboxamido, aminoalkyl, etc.; R1 = a partially unsatd. or saturated ring) are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer and the like. The invention also relates to processes for making such compds. as well as to intermediates useful in such processes. For example, I was prepared by reacting 4-(6,7-dimethoxyquinolin-4-yloxy)-3-fluorobenzenamine and

L4 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 1-methyl-3-oxo-2-phenyl-5-(pyridin-4-yl)-2,3-dihydro-1H-pyrazole-4-carboxylic acid (prepn. given). Biol. testing methods are detailed for measuring the compds. of the invention as antitumor agents, but no specific test results are given.  
 IT 913377-52-3P, N-[3-Fluoro-4-[(1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of substituted cyclic amide derivs. as protein kinase inhibitors for treating hepatocyte growth factor (HGF)-related diseases)  
 RN 913377-52-3 CAPLUS  
 CN 1H-Pyrazole-4-carboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2,3-dihydro-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2-phenyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




L4 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2006:1124107 Document No. 145:4548480 Preparation of oxalamide derivatives as kinase inhibitors for treating cancer. Borzilleri, Robert M.; Schroeder, Gretchen M.; Cornelius, Lyndon A. M. (USA). U.S. Pat. Appl. Publ. US 2006/0241104 A1 20061026, 17pp. (English). CODEN: USKXCO. APPLICATION: US 2006-406795 20060419. PRIORITY: US 2005-673727P 20050421.

GI



I




II

AB The title compds. I [R1 = H, halo, CN, etc.; R2 = H, (un)substituted alkyl or cycloalkyl; B = O, S, SO, SO2, (un)substituted NH or CH2; W and X = CH or N; Y and Z = O or S, but Y and Z cannot both be S; n = 0-4; V = (un)substituted NH2 or N-containing heterocycle; A = pyridopyridyl, pyridyl, etc.], useful for the treatment of proliferative diseases, were prepared E.g., a multi-step synthesis of II, starting from 4-chloro-1H-pyrrolo[2,3-b]pyridine and 2-fluoro-4-nitrophenol, was given. Pharmaceutical composition comprising the compound I is disclosed.  
 IT 913355-53-0P 913355-54-1P 913355-58-5P  
 913355-59-6P  
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of oxalamides as kinase inhibitors for treating cancer)  
 RN 913355-53-0 CAPLUS  
 CN Ethanediameide,  
 N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N2-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)


10582184.trn

L4 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl


RN 913355-54-1 CAPLUS  
CN Ethanediamide,  
N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N2-(2-phenylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 913355-58-5 CAPLUS  
CN Ethanediamide,  
N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N2-(phenylmethyl)- (CA INDEX NAME)


L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2006:982164 Document No. 145:3568110 Preparation of fused heterocyclic kinase inhibitors. Borzilleri, Robert M.; Chen, Zhong; Huynh, Tram N.; Vaccaro, Wayne; Chen, Xiao-Tao; Kim, Kyoung S.; Cai, Zhen-Wei (Bristol-Myers Squibb Company, USA). U.S. Pat. Appl. Publ. US 20060211695  
A1 20060921, 141 pp., Cont.-in-part of U.S. Ser. No. 167,043. (English). CODEN: USXXCO. APPLICATION: US 2005-292358 20051201. PRIORITY: US 2005-167043 20050624; US 2004-612563P 20040923; US 2004-583459P 20040628.  
GI



I




II




III

AB The title comps. I and II [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, CN, etc.; B = O, NR8, S, SO, SO2, CR9C10; V = NR11 or (CR47R48)p; W or X = C or N; Y = O, S, NR12; Z = CR13R14, (CR13R14)mNR15; m = 0-2; n = 0-4; p = 0-4, provided that if p = 0, R1 is not Ph; A = substituted pyrrolo[2,1-f][1,2,4]triazin-4-yl, pyrrolo[1,2-b]pyridazin-4-yl, pyrrolo[2,3-b]pyridin-4-yl, etc.; R3, R8, R11, R15 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl, heterocycloalkyl; R9, R10 = H, halo, alkyl, etc.; R12 = H, alkyl, CN, etc.; R13-R15, R47, R48 = H, halo, alkyl, etc.; and their pharmaceutically acceptable salts], useful as protein kinase inhibitors for treating cancer and other protein kinase mediated diseases, were prepared E.g., a multi-step synthesis of III, starting from Et 5-methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylate, was given. Comps. I and II inhibit the Met kinase with IC50 values between 0.01 to 100  $\mu$ M. Pharmaceutical comps. comprising the compound I or II alone or in combination with other antitumor agent are disclosed.

L4 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 913355-59-6 CAPLUS  
CN Ethanediamide,  
N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N2-(2-phenylethyl)- (CA INDEX NAME)




L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
IT 888719-44-6P 888719-76-4P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer)  
RN 888719-44-6 CAPLUS  
CN Benzeneacetamide,  
4-fluoro-N-[[[3-fluoro-4-[[[3-(2,2,2-trichloroacetyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 888719-76-4 CAPLUS  
CN 3-Pyridinecarboxamide, 5-bromo-1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)

10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



IT	888717-79-1P	888717-81-5P	888717-82-6P
	888717-84-8P	888718-32-9P	888718-33-0P
	888718-34-1P	888718-35-2P	888718-36-3P
	888718-37-4P	888718-38-5P	888718-39-6P
	888718-40-9P	888718-41-0P	888718-42-1P
	888718-43-2P	888718-44-3P	888718-45-4P
	888718-46-5P	888718-47-6P	888718-48-7P
	888718-49-8P	888718-50-1P	888718-51-2P
	888718-52-3P	888718-53-4P	888718-54-5P
	888718-55-6P	888718-56-7P	888718-57-8P
	888718-58-9P	888718-59-0P	888718-60-3P
	888718-61-4P	888718-62-5P	888718-63-6P
	888718-64-7P	888718-65-8P	888718-66-9P
	888718-67-0P	888718-68-1P	888718-69-2P
	888718-70-5P	888718-71-6P	888718-72-7P
	888718-73-8P	888718-74-9P	888718-75-0P
	888718-76-1P	888718-77-2P	888718-78-3P
	888718-79-4P	888718-80-7P	888718-81-8P
	888718-82-9P	888718-83-0P	888718-84-1P
	888718-85-2P	888718-86-3P	888718-87-4P
	888718-88-5P	888718-89-6P	888718-90-9P
	888718-91-0P	888718-92-1P	888718-93-2P
	888718-94-3P	888718-95-4P	888718-96-5P
	888718-97-6P	888718-98-7P	888719-00-4P
	888719-02-6P	888719-04-8P	888719-06-0P
	888719-08-2P	888719-10-6P	888719-13-9P
	888719-15-1P	888719-17-3P	888719-19-5P
	888719-20-8P	888719-22-0P	888719-23-1P
	888719-24-2P	888719-25-3P	888719-26-4P
	888719-27-5P	888719-28-6P	888719-29-7P
	888719-30-0P	888719-31-1P	888719-32-2P
	888719-33-3P	888719-34-4P	888719-36-6P

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

	888719-37-7P	888719-39-9P	888719-41-3P
	888719-42-4P	888719-43-5P	888719-45-7P
	888719-46-8P	888719-48-0P	888719-49-1P
	888719-50-4P	888719-51-5P	888719-52-6P
	888719-53-7P	888719-54-8P	888719-55-9P
	888719-59-3P	888719-61-7P	888719-63-9P
	888719-65-1P	888719-66-2P	888719-67-3P
	888719-69-5P	888719-70-8P	888719-71-9P
	888719-72-0P	888719-73-1P	888719-74-2P
	888719-75-3P	888719-77-5P	888719-78-6P
	888719-80-0P	888719-92-4P	888719-93-5P
	888719-94-6P	888719-95-7P	888719-98-0P
	888719-99-1P	888720-00-1P	888720-01-2P
	888720-02-3P	888720-03-4P	888720-04-5P
	888720-05-6P	888720-06-7P	888720-07-8P
	888720-08-9P	888720-09-0P	888720-10-3P
	888720-11-4P	888720-12-5P	888720-13-6P
	888720-14-7P	888720-15-8P	888720-16-9P
	888720-17-0P	888720-18-1P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer)

RN 888717-79-1 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl


RN 888717-81-5 CAPLUS

CN Propanediamide, N1-(4-fluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888717-80-4

CMF C22 H16 F2 N4 O3



PAGE 1-A

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 888717-82-6 CAPLUS

CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)



RN 888717-84-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 888717-83-7

CMF C19 H13 F N4 O2



10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2


CEN 76-05-1  
CMP C2 H F3 O2




RN 888718-32-9 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
N3-(3-methoxyphenyl)- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-33-0 CAPLUS  
CN Propanediamide, N1-(4-fluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]-N1-methyl- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-34-1 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
N3-3-pyridinyl- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-35-2 CAPLUS  
CN Propanediamide, N1-(2,4-difluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-36-3 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-pyridinylmethyl)- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-37-4 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-2-propen-1-yl- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-38-5 CAPLUS  
CN Propanediamide,  
N1-cyclopropyl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 2-A



RN 888718-39-6 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(2-hydroxypropyl)- (CA INDEX NAME)



RN 888718-40-9 CAPLUS  
CN Propanediamide,  
N1-(2-amino-2-methylpropyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 888718-41-0 CAPLUS  
CN Propanediamide,  
N1-[(4-fluorophenyl)methyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-42-1 CAPLUS  
CN Propanediamide,  
N1-cycloheptyl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-43-2 CAPLUS  
CN Propanediamide, N1-(2,5-dichlorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-44-3 CAPLUS  
CN Propanediamide, N1-(2-chloro-6-methylphenyl)-N3-[3-fluoro-4-(1H-  
pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-45-4 CAPLUS  
CN Propanediamide, N1-(2-chloro-6-fluorophenyl)-N3-[3-fluoro-4-(1H-  
pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-46-5 CAPLUS  
CN Propanediamide, N1-[3-(1,1-dimethylethyl)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-47-6 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 888718-48-7 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(1-methylethyl)- (CA INDEX NAME)




L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888718-49-8 CAPLUS  
CN Propanediamide, N1-(1,1-dimethylethyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)



RN 888718-50-1 CAPLUS  
CN Propanediamide, N1-cyclopentyl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




PAGE 1-A

10582184.trn


L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888718-51-2 CAPLUS  
CN Propanediamide, N1-cyclohexyl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 888718-52-3 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-phenyl- (CA INDEX NAME)


L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888718-54-5 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-2-pyridinyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-55-6 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-methyl-2-pyridinyl)- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-53-4 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-1H-pyrazol-3-yl- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A



RN 888718-56-7 CAPLUS  
CN Propanediamide, N1-(3,3-dimethylbutyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888718-57-8 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(2-hydroxyphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-58-9 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(4-methyl-2-thiazolyl)- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 888718-59-0 CAPLUS  
CN Propanediamide, N1-(5-fluoro-2-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-60-3 CAPLUS  
CN Propanediamide, N1-(4-fluoro-3-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-61-4 CAPLUS  
CN Propanediamide, N1-(4-fluoro-2-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-62-5 CAPLUS  
CN Propanediamide, N1-(3-fluoro-2-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-63-6 CAPLUS  
CN Propanediamide, N1-(2-chlorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-64-7 CAPLUS  
CN Propanediamide, N1-(2,5-difluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A



RN 888718-65-8 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-1H-indol-5-yl- (CA INDEX NAME)




RN 888718-66-9 CAPLUS

10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
 N3-[2-(1-methylethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-67-0 CAPLUS  
 CN Propanediamide, N1-[3-chloro-2-methylphenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-68-1 CAPLUS  
 CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
 N3-(phenylmethyl)- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-69-2 CAPLUS  
 CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
 N3-(2-methoxy-6-methylphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888718-70-5 CAPLUS  
 CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
 N3-(2-phenylethyl)- (CA INDEX NAME)



RN 888718-71-6 CAPLUS  
 CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
 N3-4-pyridinyl- (CA INDEX NAME)

PAGE 1-A







10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888718-72-7 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-1H-indazol-5-yl- (CA INDEX NAME)




RN 888718-73-8 CAPLUS  
CN Propanediamide, N1-[2-(aminocarbonyl)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-74-9 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-phenylpropyl)- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-75-0 CAPLUS  
CN Propanediamide, N1-[1,1'-biphenyl]-2-yl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888718-76-1 CAPLUS  
CN Propanediamide, N1-[1,1'-biphenyl]-4-yl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 888718-77-2 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-phenoxyphenyl)- (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-78-3 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-[3-(phenylmethyl)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-79-4 CAPLUS  
CN Propanediamide, N1-(3-cyanophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-80-7 CAPLUS  
CN Propanediamide, N1-(2-cyanophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-81-8 CAPLUS  
CN Propanediamide, N1-(4-cyanophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-82-9 CAPLUS  
CN Propanediamide, N1-(2,3-dihydro-1H-inden-5-yl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-83-0 CAPLUS  
CN Propanediamide, N1-(2,6-dichlorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888718-84-1 CAPLUS  
CN Propanediamide, N1-(3,4-difluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-85-2 CAPLUS  
CN Propanediamide, N1-[(1R)-2-amino-2-oxo-1-phenylethyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888718-86-3 CAPLUS  
CN Propanediamide, N1-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 888718-87-4 CAPLUS  
CN Propanediamide, N1-(5-chloro-2-fluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-88-5 CAPLUS  
CN Propanediamide,  
N1-[2-(cyanomethyl)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 888718-89-6 CAPLUS  
CN Propanediamide,  
N1-[2-(acetylamino)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-90-9 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
N3-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-91-0 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
N3-(2-furanylmethyl)- (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 888718-92-1 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-[(1R,2S)-2-hydroxycyclohexyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-93-2 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-[(1R,2S)-2-hydroxycyclohexyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888718-94-3 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-2-propyn-1-yl- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-95-4 CAPLUS  
CN Propanediamide, N1-[(1S)-2-amino-2-oxo-1-phenylethyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 888718-96-5 CAPLUS  
CN Benzanide, 2,6-difluoro-N-[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888718-97-6 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 888718-98-7 CAPLUS  
CN Propanediamide, N1-(4-fluorophenyl)-N3-[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl

RN 888719-00-4 CAPLUS  
CN 2-Pyridinecarboxamide,  
6-(4-fluorophenyl)-N-[3-fluoro-4-([2-(3-pyridinyl)-  
1H-pyrrolo[2,3-b]pyridin-4-yl]oxy)phenyl]-, 1-oxide,  
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888718-99-8  
CMF C30 H19 F2 N5 O3

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-02-6 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]-, 1-oxide, 2,2,2-trifluoroacetate (1:1) (CA  
INDEX NAME)

CM 1

CRN 888719-01-5  
CMF C25 H16 F2 N4 O3

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-04-8 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, 2,2,2-trifluoroacetate  
(1:1) (CA INDEX NAME)

CM 1

CRN 888719-03-7  
CMF C25 H16 F2 N4 O3

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-06-0 CAPLUS  
CN 2-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]-6-phenyl-, 1-oxide, 2,2,2-trifluoroacetate (1:1) (CA INDEX  
NAME)

CM 1

CRN 888719-05-9  
CMF C25 H17 F N4 O3

10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMP C2 H F3 O2



RN 888719-08-2 CAPLUS  
CN 2-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-07-1  
CMP C25 H17 F N4 O2

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMP C2 H F3 O2



RN 888719-10-6 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-1-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-09-3  
CMP C25 H17 F N4 O3

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMP C2 H F3 O2



RN 888719-13-9 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-5-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-12-8  
CMP C25 H17 F N4 O3

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2  
CRN 76-05-1  
CMP C2 H F3 O2




RN 888719-15-1 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,4-dihydro-4-oxo-5-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-14-0  
CMP C26 H19 F N4 O3

10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-17-3 CAPLUS  
CN [1(6H),3'-Bipyridine]-3-carboxamide,  
N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-,  
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-16-2  
CMF C24 H16 F N5 O3

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-19-5 CAPLUS  
CN [1(2H),2'-Bipyridine]-3-carboxamide,  
N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-,  
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-18-4  
CMF C24 H16 F N5 O3

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-20-8 CAPLUS  
CN 3-Pyridinecarboxamide, 1-[(4-fluorophenyl)methyl]-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, hydrochloride  
(1:1) (CA INDEX NAME)


L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 888719-22-0 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-[(4-fluorophenyl)methyl]-N'-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)

CM 1  
CRN 888719-21-9  
CMF C25 H20 F2 N4 O3



CM 2




10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 CRN 76-05-1  
 CMF C2 H F3 O2




RN 888719-23-1 CAPLUS  
 CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 888719-24-2 CAPLUS  
 CN 3-Pyridinecarboxamide, N-[4-[[3-(2-amino-4-thiazolyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-25-3 CAPLUS  
 CN Benzamide, N-[4-[[3-(2-amino-4-thiazolyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-2,6-difluoro- (CA INDEX NAME)




RN 888719-26-4 CAPLUS  
 CN Benzeneacetamide, N-[[[4-[[3-(2-(dimethylamino)acetyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]amino]carbonyl]-4-fluoro- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-A



L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-28-6 CAPLUS  
 CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-[[3-(2-(4-methyl-1-piperazinyloxy)acetyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 888719-29-7 CAPLUS  
 CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[3-(2-(4-methyl-1-piperazinyloxy)acetyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

RN 888719-27-5 CAPLUS  
 CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-[[3-(2-(3-hydroxy-1-pyrrolidinyl)acetyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-30-0 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-[2-(4-methyl-1-piperazinyl)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888719-32-2 CAPLUS  
CN Benzamide, 2-fluoro-N-[3-fluoro-4-[[3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-methoxy- (CA INDEX NAME)



RN 888719-33-3 CAPLUS  
CN Benzamide, 2-fluoro-N-[3-fluoro-4-[[3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)


L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888719-31-1 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-[2-(3-hydroxy-1-pyrrolidinyl)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)


PAGE 1-A



L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-34-4 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-[[3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 888719-36-6 CAPLUS  
CN Benzeneacetamide, N-[[[4-[[3-(2-amino-4-thiazolyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]amino]carbonyl]-4-fluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 888719-35-5  
CMP C25 H18 F2 N6 O3 S

10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
PAGE 1-A



PAGE 2-A




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-37-7 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888719-39-9 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(3-pyridinyl)-

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-, 1-oxide (CA INDEX NAME)




RN 888719-41-3 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1,2-dihydro-2-oxo-1-phenyl- (CA INDEX NAME)




RN 888719-42-4 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-43-5 CAPLUS  
CN Benamide, 2,6-difluoro-N-[3-fluoro-4-[[3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 888719-45-7 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide,

4-[2-fluoro-4-[[[2-(4-fluorophenyl)acetyl]amino]carbonyl]amino]phenoxy]-N-(3-pyridinylmethyl)- (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-46-8 CAPLUS  
CN 3-Pyrrolidinecarboxamide,  
1-(4-fluorophenyl)-N-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-2-oxo-2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-48-0 CAPLUS  
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-piperidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo-2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
CM 1  
CRN 888719-47-9  
CMF C30 H29 F2 N5 O3

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-49-1 CAPLUS  
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-pyrrolidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo-2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888719-50-4 CAPLUS  
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[3-[(4-hydroxy-1-piperidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-2-oxo-2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-51-5 CAPLUS  
CN Benzeneacetamide,  
4-fluoro-N-[[[3-fluoro-4-[[3-[(3-fluorophenyl)methyl]-1H-  
pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-52-6 CAPLUS  
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[3-[(3-fluorophenyl)methyl]-1H-  
pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-2-oxo- (CA  
INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-53-7 CAPLUS  
CN Benzamide, 2-fluoro-N-[3-fluoro-4-[[3-[(3-fluorophenyl)methyl]-1H-  
pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-methoxy- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



RN 888719-54-8 CAPLUS  
CN Cyclopropaneacetamide, N-[[[3-fluoro-4-[[3-[(3-fluorophenyl)methyl]-1H-  
pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A



RN 888719-55-9 CAPLUS  
CN Cyclopropanecarboxamide, N-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 888719-59-3 CAPLUS  
CN 3-Pyridinecarboxamide, N-[4-[[3-(dimethylamino)-1-propyn-1-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-58-2  
CMF C30 H23 F2 N5 O3

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-61-7 CAPLUS  
CN 3-Pyridinecarboxamide, N-[4-[[3-(dimethylamino)propyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-60-6  
CMF C30 H27 F2 N5 O3

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-63-9 CAPLUS  
CN Benzenecarboxamide, N-[[[4-[[3-(dimethylamino)-1-propyn-1-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]amino]carbonyl]-4-fluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 888719-62-8  
CMF C27 H23 F2 N5 O3

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-65-1 CAPLUS  
CN Benzanide, N-[4-[[3-(dimethylamino)-1-propyn-1-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-2,6-difluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 1

CRN 888719-64-0

CMF C25 H19 F3 N4 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 888719-66-2 CAPLUS


CN Benzamide, N-[4-[(3-cyano-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]-2-fluoro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-67-3 CAPLUS

CN Benzamide, N-[4-[(3-(5-amino-2-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]-2-fluoro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



RN 888719-69-5 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-1,2-dihydro-1-(3-methylbutyl)-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 1

CRN 888719-68-4

CMF C24 H23 F N4 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 888719-70-8 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1,2-dihydro-2-oxo-1-phenyl- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-71-9 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]-, hydrochloride (1:1) (CA INDEX NAME)




PAGE 1-A

10582184.trn


L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




● HCl

RN 888719-72-0 CAPLUS  
CN 3-Pyridinecarboxamide,  
N-[3-fluoro-4-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888719-73-1 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-N3-(4-fluorophenyl)- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl


RN 888719-75-3 CAPLUS  
CN 3-Pyridinecarboxamide,  
5-(dimethylamino)-1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888719-77-5 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-5-(4-morpholinyl)-2-oxo- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-74-2 CAPLUS  
CN 3-Pyridinecarboxamide, 5-amino-1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-78-6 CAPLUS  
CN 3-Pyridinecarboxamide, 5-[(2-aminoethyl)amino]-1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 888719-80-0 CAPLUS  
CN Propanediamide, N1-(4-fluorophenyl)-N3-[2-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1




10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
CRN 888719-79-7  
CMF C22 H16 F2 N4 O3

PAGE 1-A



PAGE 2-A




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-92-4 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-6-methyl-2-oxo- (CA INDEX NAME)




RN 888719-93-5 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxylic acid,  
4-[2-fluoro-4-[[[2-(4-fluorophenyl)acetyl]amino]carbonyl]amino]phenoxy]-,  
methyl ester (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-94-6 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888719-95-7 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(methoxymethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 888719-98-0 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2,5-difluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
CM 1  
CRN 888719-97-9  
CMF C25 H15 F3 N4 O3

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-99-1 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(2-hydroxyethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888720-00-1 CAPLUS  
CN Benzeneacetamide,  
N-[[[4-[[[3-(1,2-dihydroxyethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]amino]carbonyl]-4-fluoro- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888720-01-2 CAPLUS  
CN Benzeneacetamide,  
4-fluoro-N-[[[3-fluoro-4-[[3-(2-hydroxy-1-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888720-02-3 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[2-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 1-oxide (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

L4 ANSWER 26 OF 35 CAPLOS COPYRIGHT 2010 ACS OR SIN (CON  
 CN 2-Pyridinecarboxamide,  
 N-[2-chloro-5-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
 yloxy)phenyl]-6-(4-fluorophenyl)-, 1-oxide (CA INDEX NAME)




RN 888720-05-6 CAPLUS  
CN 2-Pyridinecarboxamide, N-[2-bromo-5-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]-6-(4-fluorophenyl)-, 1-oxide (CA INDEX NAME)




RN 888720-06-7 CAPLUS  
CN 3-Pyridinecarboxamide,  
N-[2-chloro-5-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-03-4 CAPLUS  
CN 3-Pyridinecarboxamide,  
1-[2-[3-(dimethylamino)propoxy]phenyl]-N-[3-fluoro-  
4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-,  
hydrochloride (1:1) (CA INDEX NAME)




RN 888 720-04-5 CAPLUS

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

L4 ANSWER 26 OF 35 CAPLOS COPYRIGHT 2010 ACS ON SIN (Continued)  
yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-07-8 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-bromo-5-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-08-9 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-chloro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-09-0 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-1,2-dihydro-N-[2-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo- (CA INDEX NAME)




RN 888720-10-3 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-cyano-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-13-6 CAPLUS  
CN 3-Pyridinecarboxamide, N-[5-fluoro-2-methyl-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-14-7 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-1,2-dihydro-2-oxo-N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-11-4 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-chloro-6-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-12-5 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2,6-difluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-15-8 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-2-(trifluoromethyl)phenyl]-1-oxide (CA INDEX NAME)




RN 888720-16-9 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[2-methyl-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-oxide (CA INDEX NAME)

10582184.trn

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-17-0 CAPLUS  
CN 2-Pyridinecarboxamide, N-[3-chloro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-(4-fluorophenyl)-, 1-oxide (CA INDEX NAME)




RN 888720-18-1 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-(3-hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-, ethyl ester (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888721-02-6 CAPLUS  
CN Propanoic acid, 3-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 888721-30-0 CAPLUS  
CN Benzamide, N-[4-[[3-bromo-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-2-fluoro-6-methoxy- (CA INDEX NAME)




RN 888721-31-1 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
hydrochloride (1:1) (CA INDEX NAME)




IT 888721-01-5P 888721-02-6P 888721-30-0P  
888721-31-1P 888721-39-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer)


RN 888721-01-5 CAPLUS  
CN Propanoic acid, 3-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-3-oxo- (CA INDEX NAME)



L4 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)





RN 888721-39-9 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-5-nitro-2-oxo- (CA INDEX NAME)



10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2006:534761 Document No. 145:280240 Preparation of fused heterocyclic  
 kinase inhibitors. Borzilleri, Robert M.; Chen, Zhong; Huynh, Tram N.; Vaccaro,  
 Wayne; Chen, Xiao-Tao; Kim, Kyoung S.; Cai, Zhen-Wei (Bristol-Myers  
 Squibb Co., USA). U.S. Pat. Appl. Publ. US 20050288290 A1 20051229, 141 pp.  
 (English). CODEN: USXXCO. APPLICATION: US 2005-167043 20050624.  
 PRIORITY: US 2004-612563P 20040923; US 2004-583459P 20040628.

GI




AB The title compds. I and II [R1 = H, alkyl, cycloalkyl, etc.; R2 = H,  
 halo, CN, etc.; B = O, NR8, S, SO, SO2, CR9C10; V = NR11 or (CR47R48)p; W or X  
 = C or N; Y = O, S, NR12; Z = CR13R14, (CR13R14)mNR15; m = 0-2; n = 0-4; p  
 = 0-4, provided that if p = 0, R1 is not Ph; A = substituted  
 pyrrolo[2,1-f][1,2,4]triazin-4-yl, pyrrolo[1,2-b]pyridazin-4-yl,  
 pyrrolo[2,3-b]pyridin-4-yl, etc.; R3, R8, R11, R15 = H, alkyl,  
 cycloalkyl,  
 etc.; R4 = (un)substituted aryl, heteroaryl, heterocycloalkyl; R9, R10 =  
 H, halo, alkyl, etc.; R12 = H, alkyl, CN, etc.; R13-R15, R47, R48 = H,  
 halo, alkyl, etc.; and their pharmaceutically acceptable salts], useful  
 as protein kinase inhibitors for treating cancer and other protein kinase  
 mediated diseases, were prepared E.g., a multi-step synthesis of III,  
 starting from Et  
 5-methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-  
 carboxylate, was given. Compds. I and II inhibit the Met kinase with  
 IC50

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 values between 0.01 to 100  $\mu$ M. Pharmaceutical compns. comprising the  
 compd. I or II alone or in combination with other antitumor agent are  
 disclosed.  
 IT 888719-44-6P 888719-76-4P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 [preparation of pyrrolopyridines and pyrrolotriazines as kinase  
 inhibitors for treating cancer]


RN 888719-44-6 CAPLUS  
 CN Benzeneacetamide,  
 4-fluoro-N-[[[3-fluoro-4-[[[3-(2,2,2-trichloroacetyl)-1H-  
 pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A



RN 888719-76-4 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-bromo-1-(4-fluorophenyl)-N-[[3-fluoro-4-(1H-  
 pyrrolo[2,3-b]pyridin-4-yloxy]phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)



IT 888717-79-1P 888717-81-5P 888717-82-6P  
 888717-84-8P 888718-32-9P 888718-33-0P  
 888718-34-1P 888718-35-2P 888718-36-3P  
 888718-37-4P 888718-38-5P 888718-39-6P  
 888718-40-9P 888718-41-0P 888718-42-1P  
 888718-43-2P 888718-44-3P 888718-45-4P  
 888718-46-5P 888718-47-6P 888718-48-7P  
 888718-49-8P 888718-50-1P 888718-51-2P  
 888718-52-3P 888718-53-4P 888718-54-5P  
 888718-55-6P 888718-56-7P 888718-57-8P  
 888718-58-9P 888718-59-0P 888718-60-3P  
 888718-61-4P 888718-62-5P 888718-63-6P  
 888718-64-7P 888718-65-8P 888718-66-9P  
 888718-67-0P 888718-68-1P 888718-69-2P  
 888718-70-5P 888718-71-6P 888718-72-7P  
 888718-73-8P 888718-74-9P 888718-75-0P  
 888718-76-1P 888718-77-2P 888718-78-3P  
 888718-79-4P 888718-80-7P 888718-81-8P


L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

888718-82-9P 888718-83-0P 888718-84-1P  
 888718-85-2P 888718-86-3P 888718-87-4P  
 888718-88-5P 888718-89-6P 888718-90-9P  
 888718-91-0P 888718-92-1P 888718-93-2P  
 888718-94-3P 888718-95-4P 888718-96-5P  
 888718-97-6P 888718-98-7P 888719-00-4P  
 888719-02-6P 888719-04-8P 888719-06-0P  
 888719-08-2P 888719-10-6P 888719-13-9P  
 888719-15-1P 888719-17-3P 888719-19-5P  
 888719-20-8P 888719-22-0P 888719-23-1P  
 888719-24-2P 888719-25-3P 888719-26-4P  
 888719-27-5P 888719-28-6P 888719-29-7P  
 888719-30-0P 888719-31-1P 888719-32-2P  
 888719-33-3P 888719-34-4P 888719-36-6P  
 888719-37-7P 888719-39-9P 888719-41-3P  
 888719-42-4P 888719-43-5P 888719-45-7P  
 888719-46-8P 888719-48-0P 888719-49-1P  
 888719-50-4P 888719-51-5P 888719-52-6P  
 888719-53-7P 888719-54-8P 888719-55-9P  
 888719-59-3P 888719-61-7P 888719-63-9P  
 888719-65-1P 888719-66-2P 888719-67-3P  
 888719-69-5P 888719-70-6P 888719-71-9P  
 888719-72-0P 888719-73-1P 888719-74-2P  
 888719-75-3P 888719-77-5P 888719-78-6P  
 888719-80-0P 888719-92-4P 888719-93-5P  
 888719-94-6P 888719-95-7P 888719-98-0P  
 888719-99-1P 888720-00-1P 888720-01-2P  
 888720-02-3P 888720-03-4P 888720-04-5P  
 888720-05-6P 888720-06-7P 888720-07-8P  
 888720-08-9P 888720-09-0P 888720-10-3P  
 888720-11-4P 888720-12-5P 888720-13-6P  
 888720-14-7P 888720-15-8P 888720-16-9P  
 888720-17-0P 888720-18-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (prepn. of pyrrolopyridines and pyrrolotriazines as kinase inhibitors  
 for treating cancer)  
 RN 888717-79-1 CAPLUS  
 CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
 yloxy]phenyl]amino]carbonyl]-, hydrochloride (1:1) (CA INDEX NAME)


10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl


RN 888717-81-5 CAPLUS  
CN Propanediamide, N1-(4-fluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
CM 1  
CRN 888717-80-4  
CMF C22 H16 F2 N4 O3

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 888717-82-6 CAPLUS

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)



RN 888717-84-8 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
CM 1  
CRN 888717-83-7  
CMF C19 H13 F N4 O2




CM 2

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
CRN 76-05-1  
CMF C2 H F3 O2




RN 888718-32-9 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-methoxyphenyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 888718-33-0 CAPLUS  
CN Propanediamide, N1-(4-fluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N1-methyl- (CA INDEX NAME)


10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-34-1 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-3-pyridinyl- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-35-2 CAPLUS  
CN Propanediamide, N1-(2,4-difluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-36-3 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-pyridinylmethyl)- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-37-4 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-2-propen-1-yl- (CA INDEX NAME)




10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-38-5 CAPLUS  
CN Propanediamide,  
N1-cyclopropyl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
CN Propanediamide,  
N1-[(4-fluorophenyl)methyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-42-1 CAPLUS  
CN Propanediamide,  
N1-cycloheptyl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 2-A



RN 888718-39-6 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(2-hydroxypropyl)- (CA INDEX NAME)




RN 888718-40-9 CAPLUS  
CN Propanediamide,  
N1-(2-amino-2-methylpropyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 888718-41-0 CAPLUS

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-43-2 CAPLUS  
CN Propanediamide, N1-(2,5-dichlorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-44-3 CAPLUS  
CN Propanediamide, N1-(2-chloro-6-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-45-4 CAPLUS  
CN Propanediamide, N1-(2-chloro-6-fluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-46-5 CAPLUS  
CN Propanediamide, N1-[3-(1,1-dimethylethyl)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-47-6 CAPLUS  
CN Propanediamide, N1-[3-(1,1-dimethylethyl)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)


10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-48-7 CAPLUS  
CN Propanediamide, N1-(1-methylethyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-49-8 CAPLUS  
CN Propanediamide, N1-(1,1-dimethylethyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 888718-50-1 CAPLUS  
CN Propanediamide, N1-cyclopentyl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-51-2 CAPLUS  
CN Propanediamide, N1-cyclohexyl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A



RN 888718-52-3 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-phenyl- (CA INDEX NAME)




10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888718-53-4 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-1H-pyrazol-3-yl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-54-5 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-2-pyridinyl- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 888718-55-6 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-methyl-2-pyridinyl)- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 888718-56-7 CAPLUS  
CN Propanediamide, N1-(3,3-dimethylbutyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888718-57-8 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(2-hydroxyphenyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 888718-58-9 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(4-methyl-2-thiazolyl)- (CA INDEX NAME)


10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-59-0 CAPLUS  
CN Propanediamide, N1-(5-fluoro-2-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-60-3 CAPLUS  
CN Propanediamide, N1-(4-fluoro-3-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-61-4 CAPLUS  
CN Propanediamide, N1-(4-fluoro-2-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-62-5 CAPLUS  
CN Propanediamide, N1-(3-fluoro-2-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-63-6 CAPLUS  
CN Propanediamide, N1-(2-chlorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-64-7 CAPLUS  
CN Propanediamide, N1-(2,5-difluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 888718-65-8 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-1H-indol-5-yl- (CA INDEX NAME)




RN 888718-66-9 CAPLUS

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-[2-(1-methylethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 888718-67-0 CAPLUS  
CN Propanediamide, N1-(3-chloro-2-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-68-1 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(phenylethyl)- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-69-2 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(2-methoxy-6-methylphenyl)- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888718-70-5 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(2-phenylethyl)- (CA INDEX NAME)




RN 888718-71-6 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-4-pyridinyl- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 888718-72-7 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-1H-indazol-5-yl- (CA INDEX NAME)



10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
RN 888718-73-8 CAPLUS  
CN Propanediamide, N1-[2-(aminocarbonyl)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-74-9 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-phenylpropyl)- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888718-75-0 CAPLUS  
CN Propanediamide, N1-[1,1'-biphenyl]-2-yl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888718-76-1 CAPLUS  
CN Propanediamide, N1-[1,1'-biphenyl]-4-yl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-77-2 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-phenoxyphenyl)- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-78-3 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-[3-(phenylmethyl)phenyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




PAGE 1-A




PAGE 2-A

RN 888718-79-4 CAPLUS  
CN Propanediamide, N1-(3-cyanophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




PAGE 1-A




PAGE 2-A

RN 888718-80-7 CAPLUS  
CN Propanediamide, N1-(2-cyanophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




PAGE 1-A




PAGE 2-A

RN 888718-81-8 CAPLUS  
CN Propanediamide, N1-(4-cyanophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




PAGE 1-A



PAGE 2-A


RN 888718-82-9 CAPLUS  
CN Propanediamide, N1-(2,3-dihydro-1H-inden-5-yl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 RN 888718-83-0 CAPLUS  
 CN Propanediamide, N1-(2,6-dichlorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-84-1 CAPLUS  
 CN Propanediamide, N1-(3,4-difluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-85-2 CAPLUS  
 CN Propanediamide, N1-[(1R)-2-amino-2-oxo-1-phenylethyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-86-3 CAPLUS  
 CN Propanediamide, N1-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 888718-87-4 CAPLUS  
 CN Propanediamide, N1-(2-(cyanomethyl)phenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-88-5 CAPLUS  
 CN Propanediamide, N1-[2-(cyanomethyl)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-89-6 CAPLUS  
CN Propanediamide,  
N1-[2-(acetylamino)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-90-9 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
N3-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-91-0 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
N3-(2-furanylmethyl)- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 888718-92-1 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
N3-[(1R,2R)-2-hydroxycyclohexyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.




10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 RN 888718-93-2 CAPLUS  
 CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-[(1R,2S)-2-hydroxycyclohexyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888718-94-3 CAPLUS  
 CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-2-propyn-1-yl- (CA INDEX NAME)




RN 888718-95-4 CAPLUS  
 CN Propanediamide, N1-[(1S)-2-amino-2-oxo-1-phenylethyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-96-5 CAPLUS  
 CN Benamide, 2,6-difluoro-N-[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




RN 888718-97-6 CAPLUS  
 CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-98-7 CAPLUS  
 CN Propanediamide, N1-(4-fluorophenyl)-N3-[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




● HCl

RN 888719-00-4 CAPLUS  
 CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-, 1-oxide, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888718-99-8  
 CMF C30 H19 F2 N5 O3



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2

PAGE 2-A

10582184.trn


L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-02-6 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 1-oxide, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-01-5  
CMF C25 H16 F2 N4 O3



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 1

CRN 888719-05-9  
CMF C25 H17 F N4 O3



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-08-2 CAPLUS  
CN 2-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 888719-07-1  
CMF C25 H17 F N4 O2

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888719-04-8 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-03-7  
CMF C25 H16 F2 N4 O3




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-06-0 CAPLUS  
CN 2-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-phenyl-, 1-oxide, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-10-6 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-1-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-09-3  
CMF C25 H17 F N4 O3

10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMP C2 H F3 O2



RN 888719-13-9 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-5-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-12-8  
CMP C25 H17 F N4 O3

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMP C2 H F3 O2



RN 888719-15-1 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,4-dihydro-4-oxo-5-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-14-0  
CMP C26 H19 F N4 O3

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMP C2 H F3 O2



RN 888719-17-3 CAPLUS  
CN [1(6H),3'-Bipyridine]-3-carboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-16-2  
CMP C24 H16 F N5 O3

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2  
CRN 76-05-1  
CMP C2 H F3 O2




RN 888719-19-5 CAPLUS  
CN [1(2H),2'-Bipyridine]-3-carboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-18-4  
CMP C24 H16 F N5 O3

10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-20-8 CAPLUS  
CN 3-Pyridinecarboxamide, 1-[(4-fluorophenyl)methyl]-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)


L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-23-1 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)



RN 888719-24-2 CAPLUS  
CN 3-Pyridinecarboxamide, N-[4-[[3-(2-amino-4-thiazolyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




● HCl


RN 888719-22-0 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-[(4-fluorophenyl)methyl]-N'-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 888719-21-9  
CMF C25 H20 F2 N4 O3



L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-25-3 CAPLUS  
CN Benzamide, N-[4-[[3-(2-amino-4-thiazolyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-2,6-difluoro- (CA INDEX NAME)




RN 888719-26-4 CAPLUS  
CN Benzeneacetamide, N-[[[4-[[3-[2-(dimethylamino)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]amino]carbonyl]-4-fluoro- (CA INDEX NAME)

10582184.trn


L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




RN 888719-27-5 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-[[3-[2-(3-hydroxy-1-pyrrolidinyl)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)


PAGE 2-A



L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-28-6 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-[[3-[2-(4-methyl-1-piperazinyl)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 888719-29-7 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[3-[2-(4-methyl-1-piperazinyl)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-30-0 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-[2-(4-methyl-1-piperazinyl)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888719-31-1 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-[2-(3-hydroxy-1-pyrrolidinyl)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 888719-32-2 CAPLUS  
CN Benzamide, 2-fluoro-N-[3-fluoro-4-[[3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-methoxy- (CA INDEX NAME)




10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-33-3 CAPLUS  
CN Benzamide, 2-fluoro-N-[3-fluoro-4-([3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy)phenyl]- (CA INDEX NAME)




RN 888719-34-4 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-([3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-37-7 CAPLUS

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-36-6 CAPLUS  
CN Benzeneacetamide, N-[[[4-([3-(2-amino-4-thiazolyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy)-3-fluorophenyl]amino]carbonyl]-4-fluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-35-5  
CMF C25 H18 F2 N6 O3 S

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-([3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy)phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888719-39-9 CAPLUS  
CN 2-Pyridinecarboxamide, 6-([4-fluorophenyl]-N-[3-fluoro-4-([3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy)phenyl]-, 1-oxide (CA INDEX NAME)

10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-41-3 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1,2-dihydro-2-oxo-1-phenyl- (CA INDEX NAME)




RN 888719-42-4 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




PAGE 1-A




PAGE 2-A

RN 888719-46-8 CAPLUS  
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-piperidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-43-5 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-[[3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 888719-45-7 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 4-[2-fluoro-4-[[[2-(4-fluorophenyl)acetyl]amino]carbonyl]amino]phenoxy]-N-(3-pyridinylmethyl)- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



PAGE 1-A



PAGE 2-A

RN 888719-48-0 CAPLUS  
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-piperidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 888719-47-9  
CMF C30 H29 F2 N5 O3


10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2


CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-49-1 CAPLUS  
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-pyrrolidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-50-4 CAPLUS  
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[3-[(4-hydroxy-1-piperidinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-2-oxo- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-51-5 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-[(3-fluorophenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888719-52-6 CAPLUS  
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[3-[(3-fluorophenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-2-oxo- (CA INDEX NAME)


10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-53-7 CAPLUS  
CN Benamide, 2-fluoro-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-methoxy- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-54-8 CAPLUS  
CN Cyclopropanecetamide, N-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A



RN 888719-55-9 CAPLUS  
CN Cyclopropanecarboxamide, N-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 888719-59-3 CAPLUS  
CN 3-Pyridinecarboxamide, N-[4-[[[3-(dimethylamino)-1-propyn-1-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-58-2  
CMF C30 H23 F2 N5 O3

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-61-7 CAPLUS  
CN 3-Pyridinecarboxamide, N-[4-[[[3-(dimethylamino)propyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-60-6  
CMF C30 H27 F2 N5 O3

10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-63-9 CAPLUS  
CN Benzeneacetamide, N-[[[4-[[3-(dimethylamino)-1-propyn-1-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]amino]carbonyl]-4-fluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 888719-62-8  
CMF C27 H23 F2 N5 O3

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CN Benzamide, N-[4-[[[3-(dimethylamino)-1-propyn-1-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-2,6-difluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-64-0  
CMF C25 H19 F3 N4 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-66-2 CAPLUS  
CN Benzamide, N-[4-[[[3-cyano-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-2-fluoro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-65-1 CAPLUS

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 888719-67-3 CAPLUS  
CN Benzamide, N-[4-[[[3-(5-amino-2-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-2-fluoro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)





● HCl

RN 888719-69-5 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-1-(3-methylbutyl)-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-68-4  
CMF C24 H23 F4 N4 O3


L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-72-0 CAPLUS  
CN 3-Pyridinecarboxamide,  
N-[3-fluoro-4-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



PAGE 1-A




PAGE 1-A




10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-75-3 CAPLUS  
CN 3-Pyridinecarboxamide,  
5-(dimethylamino)-1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)



RN 888719-77-5 CAPLUS


L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-80-0 CAPLUS  
CN Propanediamide, N1-(4-fluorophenyl)-N3-[2-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 888719-79-7  
CMP C22 H16 F2 N4 O3



PAGE 1-A

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-5-(4-morpholinyl)-2-oxo- (CA INDEX NAME)



RN 888719-78-6 CAPLUS  
CN 3-Pyridinecarboxamide, 5-[(2-aminoethyl)amino]-1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




PAGE 2-A

CM 2

CRN 76-05-1  
CMP C2 H F3 O2



RN 888719-92-4 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-6-methyl-2-oxo- (CA INDEX NAME)




RN 888719-93-5 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxylic acid,

10582184.trn


L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

4-[2-fluoro-4-[[[2-(4-fluorophenyl)acetyl]amino]carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 888719-94-6 CAPLUS


CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888719-95-7 CAPLUS


CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(methoxymethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 888719-98-0 CAPLUS


CN 3-Pyridinecarboxamide, N-[2,5-difluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-97-9

CMF C25 H15 F3 N4 O3

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 888719-99-1 CAPLUS


CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(2-hydroxyethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888720-00-1 CAPLUS  
CN Benzeneacetamide,  
N-[[4-[[3-(1,2-dihydroxyethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]amino]carbonyl]-4-fluoro- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888720-01-2 CAPLUS  
CN Benzeneacetamide,  
4-fluoro-N-[[[3-fluoro-4-[[3-(2-hydroxy-1-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888720-02-3 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[2-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 1-oxide (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888720-03-4 CAPLUS  
CN 3-Pyridinecarboxamide,  
1-[2-[3-(dimethylamino)propoxy]phenyl]-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 888720-04-5 CAPLUS  
CN 2-Pyridinecarboxamide,  
N-[2-chloro-5-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-(4-fluorophenyl)-, 1-oxide (CA INDEX NAME)

10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-05-6 CAPLUS  
CN 2-Pyridinecarboxamide, N-[2-bromo-5-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-(4-fluorophenyl)-, 1-oxide (CA INDEX NAME)




RN 888720-06-7 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-chloro-5-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
CN 3-Pyridinecarboxamide, N-[2-chloro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-09-0 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-1,2-dihydro-N-[2-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo- (CA INDEX NAME)




RN 888720-10-3 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-cyano-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-07-8 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-bromo-5-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-08-9 CAPLUS

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-11-4 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-chloro-6-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-12-5 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2,6-difluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-13-6 CAPLUS  
CN 3-Pyridinecarboxamide,  
N-[5-fluoro-2-methyl-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-14-7 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-1,2-dihydro-2-oxo-N-[4-(1H-  
pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 1-oxide (CA INDEX NAME)

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888720-16-9 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[2-methyl-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]-, 1-oxide (CA INDEX NAME)




RN 888720-17-0 CAPLUS  
CN 2-Pyridinecarboxamide, N-[3-chloro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]-6-(4-fluorophenyl)-, 1-oxide (CA INDEX NAME)




RN 888720-18-1 CAPLUS  
CN 3-Pyridinecarboxamide,  
N-[3-fluoro-4-[[3-(3-hydroxypropyl)-1H-pyrrolo[2,3-  
b]pyridin-4-yloxy]phenyl]amino]-3-oxo-, ethyl ester (CA INDEX NAME)


L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
pyrrolo[2,3-b]pyridin-4-yloxy)-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 888720-15-8 CAPLUS  
CN 2-Pyridinecarboxamide,  
6-(4-fluorophenyl)-N-[4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)-2-(trifluoromethyl)phenyl]-, 1-oxide (CA INDEX NAME)




L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
bipyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-,  
hydrochloride (1:1) (CA INDEX NAME)



IT 888721-01-5P 888721-02-6P 888721-30-0P  
888721-31-1P 888721-39-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of pyrrolopyridines and pyrrolotriazines as kinase  
inhibitors  
for treating cancer)


RN 888721-01-5 CAPLUS  
CN Propanoic acid, 3-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]amino]-3-oxo- (CA INDEX NAME)




RN 888721-02-6 CAPLUS  
CN Propanoic acid, 3-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]amino]-3-oxo-, ethyl ester (CA INDEX NAME)

10582184.trn

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)





RN 888721-30-0 CAPLUS  
CN Benzamide, N-[4-[[3-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-2-fluoro-6-methoxy- (CA INDEX NAME)




RN 888721-31-1 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2006:534671 Document No. 145:280230 Preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer. Borzilleri, Robert M.; Chen, Zhong; Hunt, John T.; Huynh, Tram; Poss, Michael A.; Schroeder, Gretchen M.; Vaccaro, Wayne; Wong, Tai W.; Chen, Xiao-Tao; Kim, Kyoung S. (Bristol-Myers Squibb Company, USA). U.S. Pat. Appl. Publ. US 2006004006 A1 20060105, 135 pp. (English). CODEN: USXXCO.  
APPLICATION: US 2005-167049 20050624. PRIORITY: US 2004-612563P 20040923; US 2004-583459P 20040628.  
GI




AB The title compds. I and II [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, CN, etc.; B = O, NR8, S, SO, SO2, CR9C10; V = NR11 or (CR47R48)p; W or X = C or N; Y = O, S, NR12; Z = CR13R14, (CR13R14)mNR15; m = 0-2; n = 0-4; p = 0-4, provided that if p = 0, R1 is not Ph; A = substituted pyrrolo[2,1-f][1,2,4]triazin-4-yl, pyrrolo[1,2-b]pyridazin-4-yl, pyrrolo[2,3-b]pyridin-4-yl, etc.; R3, R8, R11, R15 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl, heterocycloalkyl; R9, R10 = H, halo, alkyl, etc.; R12 = H, alkyl, CN, etc.; R13-R15, R47, R48 = H, halo, alkyl, etc.; and their pharmaceutically acceptable salts], useful as protein kinase inhibitors for treating cancer and other protein kinase mediated diseases, were prepared E.g., a multi-step synthesis of III, starting from Et 5-methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylate, was given. Compds. I and II inhibit the Met kinase with IC50 values between 0.01 to 100  $\mu$ M. Pharmaceutical compns. comprising the

L4 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888721-39-9 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-5-nitro-2-oxo- (CA INDEX NAME)




L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
compd. I or II alone or in combination with other antitumor agent are disclosed.  
IT 888719-44-6P 888719-76-4P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer)  
RN 888719-44-6 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(2,2,2-trichloroacetyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 888719-76-4 CAPLUS  
CN 3-Pyridinecarboxamide, 5-bromo-1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)

10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




IT 888717-79-1P 888717-81-5P 888717-82-6P  
888717-84-8P 888718-32-9P 888718-33-0P  
888718-34-1P 888718-35-2P 888718-36-3P  
888718-37-4P 888718-38-5P 888718-39-6P  
888718-40-9P 888718-41-0P 888718-42-1P  
888718-43-2P 888718-44-3P 888718-45-4P  
888718-46-5P 888718-47-6P 888718-48-7P  
888718-49-8P 888718-50-1P 888718-51-2P  
888718-52-3P 888718-53-4P 888718-54-5P  
888718-55-6P 888718-56-7P 888718-57-8P  
888718-58-9P 888718-59-0P 888718-60-3P  
888718-61-4P 888718-62-5P 888718-63-6P  
888718-64-7P 888718-65-8P 888718-66-9P  
888718-67-0P 888718-68-1P 888718-69-2P  
888718-70-5P 888718-71-6P 888718-72-7P  
888718-73-8P 888718-74-9P 888718-75-0P  
888718-76-1P 888718-77-2P 888718-78-3P  
888718-79-4P 888718-80-7P 888718-81-8P  
888718-82-9P 888718-83-0P 888718-84-1P  
888718-85-2P 888718-86-3P 888718-87-4P  
888718-88-5P 888718-89-6P 888718-90-9P  
888718-91-0P 888718-92-1P 888718-93-2P  
888718-94-3P 888718-95-4P 888718-96-5P  
888718-97-6P 888718-98-7P 888719-00-4P  
888719-02-6P 888719-04-8P 888719-06-0P  
888719-08-2P 888719-10-6P 888719-13-9P  
888719-15-1P 888719-17-3P 888719-19-5P  
888719-20-8P 888719-22-0P 888719-23-1P  
888719-24-2P 888719-25-3P 888719-26-4P  
888719-27-5P 888719-28-6P 888719-29-7P

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

888719-30-0P 888719-31-1P 888719-32-2P  
888719-33-3P 888719-34-4P 888719-36-6P  
888719-37-7P 888719-39-9P 888719-41-3P  
888719-42-4P 888719-43-5P 888719-45-7P  
888719-46-8P 888719-48-0P 888719-49-1P  
888719-50-4P 888719-51-5P 888719-52-6P  
888719-53-7P 888719-54-8P 888719-55-9P  
888719-59-3P 888719-61-7P 888719-63-9P  
888719-65-1P 888719-66-2P 888719-67-3P  
888719-69-5P 888719-70-8P 888719-71-9P  
888719-72-0P 888719-73-1P 888719-74-2P  
888719-75-3P 888719-77-5P 888719-78-6P  
888719-80-0P 888719-92-4P 888719-93-5P  
888719-94-6P 888719-95-7P 888719-98-0P  
888719-99-1P 888720-00-1P 888720-01-2P  
888720-02-3P 888720-03-4P 888720-04-5P  
888720-05-6P 888720-06-7P 888720-07-8P  
888720-08-9P 888720-09-0P 888720-10-3P  
888720-11-4P 888720-12-5P 888720-13-6P  
888720-14-7P 888720-15-8P 888720-16-9P  
888720-17-0P 888720-18-1P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(prepn. of pyrrolopyridines and pyrrolotriazines as kinase inhibitors  
for treating cancer)  
RN 888717-79-1 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]amino]carbonyl]-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl

RN 888717-81-5 CAPLUS  
CN Propanediamide, N1-(4-fluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
CM 1  
CRN 888717-80-4  
CMF C22 H16 F2 N4 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 888717-82-6 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]- (CA INDEX NAME)

10582184.trn


L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888717-84-8 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888717-83-7  
CMF C19 H13 F N4 O2



CM 2


L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CRN 76-05-1  
CMF C2 H F3 O2




RN 888718-32-9 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-methoxyphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-33-0 CAPLUS  
CN Propanediamide, N1-(4-fluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
b]pyridin-4-yloxy)phenyl]-N1-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-34-1 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-3-pyridinyl- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-35-2 CAPLUS  
CN Propanediamide, N1-(2,4-difluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-36-3 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-pyridinylmethyl)- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-37-4 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-2-propen-1-yl- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-38-5 CAPLUS  
CN Propanediamide,  
N1-cyclopropyl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 2-A



RN 888718-39-6 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(2-hydroxypropyl)- (CA INDEX NAME)



RN 888718-40-9 CAPLUS  
CN Propanediamide,  
N1-(2-amino-2-methylpropyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 888718-41-0 CAPLUS  
CN Propanediamide,  
N1-[(4-fluorophenyl)methyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-42-1 CAPLUS  
CN Propanediamide,  
N1-cycloheptyl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-43-2 CAPLUS  
CN Propanediamide, N1-(2,5-dichlorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-44-3 CAPLUS  
CN Propanediamide, N1-(2-chloro-6-methylphenyl)-N3-[3-fluoro-4-(1H-  
pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-45-4 CAPLUS  
CN Propanediamide, N1-(2-chloro-6-fluorophenyl)-N3-[3-fluoro-4-(1H-  
pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)



10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-46-5 CAPLUS  
CN Propanediamide, N1-[3-(1,1-dimethylethyl)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 888718-47-6 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 888718-48-7 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(1-methylethyl)- (CA INDEX NAME)




L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888718-49-8 CAPLUS  
CN Propanediamide, N1-(1,1-dimethylethyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)



RN 888718-50-1 CAPLUS  
CN Propanediamide, N1-cyclopentyl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


PAGE 1-A



10582184.trn


L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888718-51-2 CAPLUS  
CN Propanediamide, N1-cyclohexyl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 888718-52-3 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-phenyl- (CA INDEX NAME)


L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888718-54-5 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-2-pyridinyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-55-6 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-methyl-2-pyridinyl)- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-53-4 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-1H-pyrazol-3-yl- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A



RN 888718-56-7 CAPLUS  
CN Propanediamide, N1-(3,3-dimethylbutyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888718-57-8 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(2-hydroxyphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-58-9 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(4-methyl-2-thiazolyl)- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 888718-59-0 CAPLUS  
CN Propanediamide, N1-(5-fluoro-2-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-60-3 CAPLUS  
CN Propanediamide, N1-(4-fluoro-3-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-61-4 CAPLUS  
CN Propanediamide, N1-(4-fluoro-2-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-62-5 CAPLUS  
CN Propanediamide, N1-(3-fluoro-2-methylphenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-63-6 CAPLUS  
CN Propanediamide, N1-(2-chlorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-64-7 CAPLUS  
CN Propanediamide, N1-(2,5-difluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A



RN 888718-65-8 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-1H-indol-5-yl- (CA INDEX NAME)




RN 888718-66-9 CAPLUS

10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
 N3-[2-(1-methylethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-67-0 CAPLUS  
 CN Propanediamide, N1-[3-chloro-2-methylphenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-68-1 CAPLUS  
 CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
 N3-(phenylmethyl)- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-69-2 CAPLUS  
 CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
 N3-(2-methoxy-6-methylphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888718-70-5 CAPLUS  
 CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
 N3-(2-phenylethyl)- (CA INDEX NAME)



RN 888718-71-6 CAPLUS  
 CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
 N3-4-pyridinyl- (CA INDEX NAME)


PAGE 1-A




10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888718-72-7 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-1H-indazol-5-yl- (CA INDEX NAME)




RN 888718-73-8 CAPLUS  
CN Propanediamide, N1-[2-(aminocarbonyl)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-74-9 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-phenylpropyl)- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-75-0 CAPLUS  
CN Propanediamide, N1-[1,1'-biphenyl]-2-yl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888718-76-1 CAPLUS  
CN Propanediamide, N1-[1,1'-biphenyl]-4-yl-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 888718-77-2 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-(3-phenoxyphenyl)- (CA INDEX NAME)


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-78-3 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-[3-(phenylmethyl)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-79-4 CAPLUS  
CN Propanediamide, N1-(3-cyanophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-80-7 CAPLUS  
CN Propanediamide, N1-(2-cyanophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-81-8 CAPLUS  
CN Propanediamide, N1-(4-cyanophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-82-9 CAPLUS  
CN Propanediamide, N1-(2,3-dihydro-1H-inden-5-yl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-83-0 CAPLUS  
CN Propanediamide, N1-(2,6-dichlorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888718-84-1 CAPLUS  
CN Propanediamide, N1-(3,4-difluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888718-85-2 CAPLUS  
CN Propanediamide, N1-[(1R)-2-amino-2-oxo-1-phenylethyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888718-86-3 CAPLUS  
CN Propanediamide, N1-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 888718-87-4 CAPLUS  
CN Propanediamide, N1-(5-chloro-2-fluorophenyl)-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-88-5 CAPLUS  
CN Propanediamide,  
N1-[2-(cyanomethyl)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 888718-89-6 CAPLUS  
CN Propanediamide,  
N1-[2-(acetylamino)phenyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888718-90-9 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
N3-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888718-91-0 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
N3-(2-furanylmethyl)- (CA INDEX NAME)


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 888718-92-1 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-[(1R,2S)-2-hydroxycyclohexyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-93-2 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-[(1R,2S)-2-hydroxycyclohexyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888718-94-3 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-N3-2-propyn-1-yl- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888718-95-4 CAPLUS  
CN Propanediamide, N1-[(1S)-2-amino-2-oxo-1-phenylethyl]-N3-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 888718-96-5 CAPLUS  
CN Benzanide, 2,6-difluoro-N-[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888718-97-6 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 888718-98-7 CAPLUS  
CN Propanediamide, N1-(4-fluorophenyl)-N3-[3-fluoro-4-[[2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● HCl

RN 888719-00-4 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[3-fluoro-4-([2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy)phenyl]-, 1-oxide, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888718-99-8  
CMF C30 H19 F2 N5 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-02-6 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 1-oxide, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-01-5  
CMF C25 H16 F2 N4 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-04-8 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-03-7  
CMF C25 H16 F2 N4 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-06-0 CAPLUS  
CN 2-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-phenyl-, 1-oxide, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-05-9  
CMF C25 H17 F N4 O3

10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMP C2 H F3 O2



RN 888719-08-2 CAPLUS  
CN 2-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-07-1  
CMP C25 H17 F N4 O2

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMP C2 H F3 O2



RN 888719-10-6 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-1-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-09-3  
CMP C25 H17 F N4 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMP C2 H F3 O2



RN 888719-13-9 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-5-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-12-8  
CMP C25 H17 F N4 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2  
CRN 76-05-1  
CMP C2 H F3 O2




RN 888719-15-1 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,4-dihydro-4-oxo-5-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-14-0  
CMP C26 H19 F N4 O3

10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-17-3 CAPLUS  
CN [1(6H),3'-Bipyridine]-3-carboxamide,  
N-[(3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-2-oxo-2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)]-3-carboxamide, [1(6H),3'-Bipyridine]-3-carboxamide, N-[(3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-2-oxo-2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)]-3-carboxamide, [1(6H),3'-Bipyridine]-3-carboxamide

CM 1  
CRN 888719-16-2  
CMF C24 H16 F N5 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-19-5 CAPLUS  
CN [1(2H),2'-Bipyridine]-3-carboxamide,  
N-[(3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-2-oxo-2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)]-3-carboxamide, [1(2H),2'-Bipyridine]-3-carboxamide, N-[(3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-2-oxo-2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)]-3-carboxamide, [1(2H),2'-Bipyridine]-3-carboxamide

CM 1  
CRN 888719-18-4  
CMF C24 H16 F N5 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-20-8 CAPLUS  
CN 3-Pyridinecarboxamide, 1-[(4-fluorophenyl)methyl]-N-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-1,2-dihydro-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)


L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl

RN 888719-22-0 CAPLUS  
CN 1,1-Cyclopropanedicarboxamide, N-[(4-fluorophenyl)methyl]-N'-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1  
CRN 888719-21-9  
CMF C25 H20 F2 N4 O3




CM 2

10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 CRN 76-05-1  
 CMF C2 H F3 O2




RN 888719-23-1 CAPLUS  
 CN 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 888719-24-2 CAPLUS  
 CN 3-Pyridinecarboxamide, N-[4-[[3-(2-amino-4-thiazolyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-27-5 CAPLUS  
 CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-[[3-[2-(3-hydroxy-1-pyrrolidinyl)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-25-3 CAPLUS  
 CN Benzamide, N-[4-[[3-(2-amino-4-thiazolyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-2,6-difluoro- (CA INDEX NAME)




RN 888719-26-4 CAPLUS  
 CN Benzeneacetamide, N-[[[4-[[3-[2-(dimethylamino)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]amino]carbonyl]-4-fluoro- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-28-6 CAPLUS  
 CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-[[3-[2-(4-methyl-1-piperazinyl)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)



RN 888719-29-7 CAPLUS  
 CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[3-[2-(4-methyl-1-piperazinyl)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-30-0 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-[2-(4-methyl-1-piperazinyl)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A



RN 888719-32-2 CAPLUS  
CN Benzamide, 2-fluoro-N-[3-fluoro-4-[[3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-6-methoxy- (CA INDEX NAME)



RN 888719-33-3 CAPLUS  
CN Benzamide, 2-fluoro-N-[3-fluoro-4-[[3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)


L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 888719-31-1 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-[2-(3-hydroxy-1-pyrrolidinyl)acetyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)


PAGE 1-A



L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-34-4 CAPLUS  
CN Benzamide, 2,6-difluoro-N-[3-fluoro-4-[[3-(4-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 888719-36-6 CAPLUS  
CN Benzeneacetamide, N-[[[4-[[3-(2-amino-4-thiazolyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]amino]carbonyl]-4-fluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 888719-35-5  
CMP C25 H18 F2 N6 O3 S

10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
PAGE 1-A



PAGE 2-A




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-37-7 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 888719-39-9 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(3-pyridinyl)-

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-, 1-oxide (CA INDEX NAME)




RN 888719-41-3 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1,2-dihydro-2-oxo-1-phenyl- (CA INDEX NAME)




RN 888719-42-4 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[[3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-43-5 CAPLUS  
CN Benamide, 2,6-difluoro-N-[3-fluoro-4-[[3-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)



RN 888719-45-7 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide,


4-[2-fluoro-4-[[[2-(4-fluorophenyl)acetyl]amino]carbonyl]amino]phenoxy]-N-(3-pyridinylmethyl)- (CA INDEX NAME)




10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-46-8 CAPLUS  
CN 3-Pyrrolidinecarboxamide,  
1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-  
b]pyridin-4-yloxy)phenyl]-2-oxo- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 888719-48-0 CAPLUS  
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-  
piperidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo-,  
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
CM 1  
CRN 888719-47-9  
CMF C30 H29 F2 N5 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-49-1 CAPLUS  
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-  
pyrrolidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo- (CA  
INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888719-50-4 CAPLUS  
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[3-[(4-hydroxy-1-  
piperidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-  
fluorophenyl)-2-oxo- (CA INDEX NAME)


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-51-5 CAPLUS  
CN Benzeneacetamide,  
4-fluoro-N-[[[3-fluoro-4-[[3-[(3-fluorophenyl)methyl]-1H-  
pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-52-6 CAPLUS  
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[3-[(3-fluorophenyl)methyl]-1H-  
pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-2-oxo- (CA  
INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-53-7 CAPLUS  
CN Benzamide, 2-fluoro-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]-6-methoxy- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



RN 888719-54-8 CAPLUS  
CN Cyclopropaneacetamide, N-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]amino]carbonyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A



RN 888719-55-9 CAPLUS  
CN Cyclopropanecarboxamide, N-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 888719-59-3 CAPLUS  
CN 3-Pyridinecarboxamide, N-[4-[[3-(dimethylamino)-1-propyn-1-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl)-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-58-2  
CMF C30 H23 F2 N5 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-61-7 CAPLUS  
CN 3-Pyridinecarboxamide, N-[4-[[3-(dimethylamino)propyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl)-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 888719-60-6  
CMF C30 H27 F2 N5 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-63-9 CAPLUS  
CN Benzenecarboxamide, N-[[[4-[[3-(dimethylamino)-1-propyn-1-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]amino]carbonyl]-4-fluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 888719-62-8  
CMF C27 H23 F2 N5 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 888719-65-1 CAPLUS  
CN Benzenamide, N-[4-[[3-(dimethylamino)-1-propyn-1-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl)-2,6-difluoro-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 1

CRN 888719-64-0

CMF C25 H19 F3 N4 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 888719-66-2 CAPLUS


CN Benzamide, N-[4-[(3-cyano-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]-2-fluoro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-67-3 CAPLUS

CN Benzamide, N-[4-[(3-(5-amino-2-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]-2-fluoro-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



RN 888719-69-5 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)phenyl]-1,2-dihydro-1-(3-methylbutyl)-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CM 1

CRN 888719-68-4

CMF C24 H23 F N4 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 888719-70-8 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-fluoro-4-[(2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-1,2-dihydro-2-oxo-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-71-9 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[(2-(3-pyridinyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]amino]carbonyl]-, hydrochloride (1:1) (CA INDEX NAME)




PAGE 1-A

10582184.trn


L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




● HCl

RN 888719-72-0 CAPLUS  
CN 3-Pyridinecarboxamide,  
N-[3-fluoro-4-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888719-73-1 CAPLUS  
CN Propanediamide, N1-[3-fluoro-4-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-N3-(4-fluorophenyl)- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl


RN 888719-75-3 CAPLUS  
CN 3-Pyridinecarboxamide,  
5-(dimethylamino)-1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888719-77-5 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-5-(4-morpholinyl)-2-oxo- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-74-2 CAPLUS  
CN 3-Pyridinecarboxamide, 5-amino-1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 888719-78-6 CAPLUS  
CN 3-Pyridinecarboxamide, 5-[(2-aminoethyl)amino]-1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 888719-80-0 CAPLUS  
CN Propanediamide, N1-(4-fluorophenyl)-N3-[2-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
CRN 888719-79-7  
CMF C22 H16 F2 N4 O3

PAGE 1-A



PAGE 2-A




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888719-92-4 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-6-methyl-2-oxo- (CA INDEX NAME)




RN 888719-93-5 CAPLUS  
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxylic acid,  
4-[2-fluoro-4-[[[2-(4-fluorophenyl)acetyl]amino]carbonyl]amino]phenoxy]-,  
methyl ester (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888719-94-6 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888719-95-7 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(methoxymethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 888719-98-0 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2,5-difluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
CM 1  
CRN 888719-97-9  
CMF C25 H15 F3 N4 O3

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




CM 2  
CRN 76-05-1  
CMF C2 H F3 O2




RN 888719-99-1 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(2-hydroxyethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888720-00-1 CAPLUS  
CN Benzeneacetamide, N-[[[4-[[[3-(1,2-dihydroxyethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]amino]carbonyl]-4-fluoro- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 888720-01-2 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[3-(2-hydroxy-1-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]amino]carbonyl]- (CA INDEX NAME)


10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 888720-02-3 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[2-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 1-oxide (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-03-4 CAPLUS  
CN 3-Pyridinecarboxamide, 1-[2-[3-(dimethylamino)propoxy]phenyl]-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-, hydrochloride (1:1) (CA INDEX NAME)




RN 888720-04-5 CAPLUS

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CN 2-Pyridinecarboxamide, N-[2-chloro-5-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-(4-fluorophenyl)-, 1-oxide (CA INDEX NAME)




RN 888720-05-6 CAPLUS  
CN 2-Pyridinecarboxamide, N-[2-bromo-5-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-(4-fluorophenyl)-, 1-oxide (CA INDEX NAME)




RN 888720-06-7 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-chloro-5-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)



RN 888720-07-8 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-bromo-5-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-08-9 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-chloro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-09-0 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-1,2-dihydro-N-[2-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo- (CA INDEX NAME)




RN 888720-10-3 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-cyano-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-13-6 CAPLUS  
CN 3-Pyridinecarboxamide, N-[5-fluoro-2-methyl-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-14-7 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-1,2-dihydro-2-oxo-N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-11-4 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2-chloro-6-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)




RN 888720-12-5 CAPLUS  
CN 3-Pyridinecarboxamide, N-[2,6-difluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-15-8 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)-2-(trifluoromethyl)phenyl]-1-oxide (CA INDEX NAME)




RN 888720-16-9 CAPLUS  
CN 2-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[2-methyl-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1-oxide (CA INDEX NAME)

10582184.trn

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888720-17-0 CAPLUS  
CN 2-Pyridinecarboxamide, N-[3-chloro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-6-(4-fluorophenyl)-, 1-oxide (CA INDEX NAME)




RN 888720-18-1 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-(3-hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-2-oxo-, ethyl ester (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 888721-02-6 CAPLUS  
CN Propanoic acid, 3-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 888721-30-0 CAPLUS  
CN Benzamide, N-[4-[[3-bromo-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]-2-fluoro-6-methoxy- (CA INDEX NAME)




RN 888721-31-1 CAPLUS  
CN 3-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)

L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
hydrochloride (1:1) (CA INDEX NAME)




IT 888721-01-5P 888721-02-6P 888721-30-0P  
888721-31-1P 888721-39-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer)


RN 888721-01-5 CAPLUS  
CN Propanoic acid, 3-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-3-oxo- (CA INDEX NAME)



L4 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 888721-39-9 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-5-nitro-2-oxo- (CA INDEX NAME)




10582184.trn

L4 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2006:220099 Document No. 144:4327060 Synthesis of 4-substituted 7-azaindole derivatives via Pd-catalyzed C-N and C-O coupling. Thutewohl, Michael; Schiroke, Hartmut; Bennabi, Samir; Figueroa-Perez, Santiago (Pharma Research, Bayer HealthCare AG, Wuppertal, 42096, Germany). Synthesis (4), 629-632 (English) 2006. CODEN: SYNTBF. ISSN: 0039-7881. OTHER SOURCES: CASREACT 144:432706. Publisher: Georg Thieme Verlag.

GI



AB The efficient substitution of 4-chloro-7-azaindoles by anilines and phenols via palladium-catalyzed C-N and C-O coupling is reported. E.g., Pd2(dba)3 catalyzed the substitution of 4-chloro-7-azaindole by 2-fluoro-4-nitroaniline to give 78% 4-arylamino-7-azaindole derivative I.  
 IT 885327-74-2P 885327-77-5P  
 RI: SPN (Synthetic preparation); PREP (Preparation)  
 (substitution of 4-chloro-7-azaindoles by anilines and phenols via palladium-catalyzed C-N and C-O coupling)  
 RN 885327-74-2 CAPLUS  
 CN Acetamide, N-[3-fluoro-4-[[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)



RN 885327-77-5 CAPLUS  
 CN Carbamic acid, [3-fluoro-4-[[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-


L4 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2005:1215922 Document No. 143:4601790 Preparation of substituted phenylaminopyrimidines for use as cardiovascular agents. Schiroke, Hartmut; Stasch, Johannes-Peter; Kast, Raimund; Muentter, Klaus; Gnoth, Mark Jean; Figueroa Perez, Santiago; Thutewohl, Michael; Bennabi, Samir; Lang, Dieter; Mittendorf, Joachim; Radtke, Martin; Ehnke, Heimo (Bayer Healthcare A.-G., Germany). PCT Int. Appl. WO 2005108397 A1 20051117,  
 117 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RM: AT, BE, BF, BG, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2. APPLICATION: WO 2005-EP3925 20050414. PRIORITY: DE 2004-102004020570 20040427.

GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to substituted phenylaminopyrimidines I [X = NR6, CR7R8, C(=O); R1 = H, halogen, CN, (un)substituted C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxycarbonyl, C1-6-alkylaminocarbonyl; R2 = F, Cl; R3 = H, OH, halogen, CF3, CF2CF3, (un)substituted C1-6-alkyl, C1-6-alkoxy, C3-8-cycloalkyl, C6-10-aryl, C6-10-aryloxy, 5- to 10-membered heteroaryl, heteroaryloxy, heterocyclyl, NR11R12, C(=O)R19; R4 = H, F, Cl; R5 = H, Cl-6-alkyl; R6 = H, Cl-3-alkyl; R7, R8 = H, Me; R12, R12 = H, Cl-6-alkyl, C3-8-cycloalkyl, 5- to 10-membered heteroaryl; NR11R12 = 4- to 6-membered heterocycle, 7- to 12-membered bi- or tricyclic heterocycle; R19 = Cl-6-alkoxy, Cl-6-alkylamino, N-(monocyclic heterocycle), N-(bicyclic heterocycle); dashed line = single or double bond] or their salts, solvates or salt solvates, to a method for their production and to their use for producing medicaments for the treatment and/or prophylaxis of diseases in humans and animals, in particular for the treatment of cardiovascular diseases. The method for their preparation comprises: reaction of [4-(1H-pyrrolo[2,3-b]pyridin-4-yl)methyl]aniline derivs. II with pyrimidines III. Thus, 4-(3-fluoroanilino)-2-pyrimidinamine derivative IV was prepared from 3-fluoro-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)methyl]aniline V via amination of 4-chloro-6-(trifluoromethyl)pyridin-2-amine in aqueous HCl. Aniline V was prepared from 1H-pyrrolo[2,3-b]pyridine via N-oxidation with 3-ClC6H4CO2OH in CH2Cl2, regioselective nitration, N-alkylation with ClCH2OCH2CH2SiMe3 in DMF containing NaH, regioselective chlorination with ClCO2Me in THF containing hexamethyldisilazane, nucleophilic substitution with 3-F-4-O2NC6H3CH2CO2Me, decarbonylation with LiOH in wet MeOH, hydrogenolysis in EtOH containing Et3N and catalytic Pd/C and N-deprotection with with CF3CO2H in CH2Cl2. The bioactivity of II was determined [IC50 = 7 nM]


L4 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 vs. Rho-kinase II (ROKα); IC50 = 86 nM vs. blood vessel contraction (in vitro)].  
 IT 869335-62-6P  
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and N-deprotection of; preparation of substituted phenylaminopyrimidines for use as cardiovascular agents)  
 RN 869335-62-6 CAPLUS  
 CN Acetamide, N-[4-[[3-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]methyl]-3-fluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)




IT 869335-65-9P  
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and N-tosylation of; preparation of substituted phenylaminopyrimidines for use as cardiovascular agents)  
 RN 869335-65-9 CAPLUS  
 CN Acetamide, N-[4-[(3-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)methyl]-3-fluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)



IT 869335-64-8P

10582184.trn

L4 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and regioselective N-deprotection of; prepn. of substituted  
 phenylaminopyrimidines for use as cardiovascular agents)  
 RN 869335-64-8 CAPLUS  
 CN Acetamide, N-[4-[[3-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-  
 pyrrolo[2,3-b]pyridin-4-yl]methyl]-3-fluorophenyl]-2,2,2-trifluoro- (CA  
 INDEX NAME)



IT 869335-61-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and regioselective chlorination or bromination of;  
 preparation of  
 substituted phenylaminopyrimidines for use as cardiovascular agents)  
 RN 869335-61-5 CAPLUS  
 CN Acetamide, 2,2,2-trifluoro-N-[3-fluoro-4-[[1-[[2-  
 (trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-  
 yl]methyl]phenyl]- (CA INDEX NAME)


L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
 2005:1130634 Document No. 143:4059190 Preparation of  
 heteroaryloxy-substituted phenylamino pyrimidines as Rho kinase  
 inhibitors. Schirok, Hartmut; Radtke, Martin; Mittendorf, Joachim; Kast,  
 Raimund; Stasch, Johannes-Peter; Gnoth, Mark Jean; Muentzer, Klaus; Lang,  
 Dieter; Figueroa Perez, Santiago; Thutewohl, Michael; Bennabi, Samir;  
 Elmke, Heimo (Bayer Healthcare A.-G., Germany). PCT Int. Appl. WO  
 2005097790 A1 20051020, 82 pp. DESIGNATED STATES: W: AE, AG, AL, AM,  
 AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,  
 DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
 MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,  
 SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,  
 ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR,  
 GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.  
 (German). CODEN: PIXXD2. APPLICATION: WO 2005-EF3294 20050330.  
 PRIORITY: DE 2004-102004017438 20040408.  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title comps. I [R1 = Cl, Br, CN, etc.; R2 = H or F; R3 = H, Cl, CF3,  
 etc.] and their pharmaceutically acceptable salts, are prepared and  
 disclosed as Rho kinase inhibitors. Thus, e.g., II was prepared by  
 coupling  
 of 3,5-difluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]aniline  
 (preparation given) with 4,6-dichloropyrimidin-2-amine. The inhibitory  
 activity of I towards Rho kinase was evaluated using scintillation assay  
 and it was revealed that selected comps. of the invention possessed IC50  
 values in the range of 2 up to 7 nM. I as Rho kinase inhibitors should  
 prove useful in the treatment of cardiovascular disease and erectile  
 dysfunction. Pharmaceutical comps. comprising I are disclosed.  
 IT 855863-41-1P 855863-43-3P 855863-45-5P  
 855863-85-3P 855863-87-5P 855863-91-1P  
 867017-93-4P 867017-94-5P 867017-95-6P  
 867017-96-7P 867017-98-9P 867018-00-6P  
 867018-02-8P 867018-06-2P 867018-08-4P  
 867018-09-5P 867018-11-9P 867018-13-1P  
 867018-14-2P 867018-16-4P 867018-17-5P  
 867018-19-7P 867018-20-0P 867018-22-2P  
 867018-24-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of heteroaryloxy-substituted phenylamino pyrimidines as

Rho  
 Kinase inhibitors)  
 RN 855863-41-1 CAPLUS  
 CN Acetamide, N-[3-fluoro-4-[[1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-  
 b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)


L4 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




IT 869335-66-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation, cyanation and N-deacetylation of; preparation of  
 substituted  
 phenylaminopyrimidines for use as cardiovascular agents)  
 RN 869335-66-0 CAPLUS  
 CN Acetamide, N-[4-[[3-bromo-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-  
 b]pyridin-4-yl]methyl]-3-fluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)




L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 855863-43-3 CAPLUS  
 CN Acetamide, N-[4-[[3-bromo-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-  
 b]pyridin-4-yl]oxy]-3-fluorophenyl]- (CA INDEX NAME)




RN 855863-45-5 CAPLUS  
 CN Acetamide, N-[3-fluoro-4-[[3-methyl-1-[(4-methylphenyl)sulfonyl]-1H-  
 pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 RN 855863-85-3 CAPLUS  
 CN Acetamide, N-[3,5-difluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 855863-87-5 CAPLUS  
 CN Acetamide, N-[4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 855863-91-1 CAPLUS  
 CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
 RN 867017-95-6 CAPLUS  
 CN Acetamide, N-[4-[(3-bromo-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]- (CA INDEX NAME)




RN 867017-96-7 CAPLUS  
 CN Acetamide, N-[3,5-difluoro-4-[[3-methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 867017-98-9 CAPLUS  
 CN Acetamide, N-[4-[(3-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]- (CA INDEX NAME)


L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 867017-93-4 CAPLUS  
 CN Acetamide, N-[3,5-difluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 867017-94-5 CAPLUS  
 CN Acetamide, N-[4-[(3-bromo-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]- (CA INDEX NAME)




L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 867018-00-6 CAPLUS  
 CN Acetamide, 2,2,2-trifluoro-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 867018-02-8 CAPLUS  
 CN Acetamide, N-[4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3-fluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)




10582184.trn

L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 867018-06-2 CAPLUS  
CN Acetamide, N-[4-[[3-cyclopropyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]- (CA INDEX NAME)




RN 867018-08-4 CAPLUS  
CN Acetamide, N-[4-[[3-ethenyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]- (CA INDEX NAME)




RN 867018-09-5 CAPLUS  
CN Acetamide, N-[4-[[3-ethyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]- (CA INDEX NAME)

L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 867018-11-9 CAPLUS  
CN Acetamide, N-[3-fluoro-4-[[3-(2-hydroxyethyl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 867018-13-1 CAPLUS  
CN Acetamide, N-[3-fluoro-4-[[1-[(4-methylphenyl)sulfonyl]-3-[2-[(4-methylphenyl)sulfonyl]oxy]ethyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)

L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 867018-14-2 CAPLUS  
CN Acetamide, N-[3-fluoro-4-[[3-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 867018-16-4 CAPLUS  
CN Acetamide, N-[4-[[3-cyano-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]- (CA INDEX NAME)


L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 867018-17-5 CAPLUS  
CN Acetamide, N-[4-[[3-cyano-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]- (CA INDEX NAME)




RN 867018-19-7 CAPLUS  
CN Acetamide, N-[4-[[3-cyano-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3,5-difluorophenyl]- (CA INDEX NAME)




RN 867018-20-0 CAPLUS

10582184.trn

L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
CN Acetamide, N-[4-[(3-cyano-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]- (CA INDEX NAME)



RN 867018-22-2 CAPLUS  
CN Acetamide, N-[4-[(3-cyclopropyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]- (CA INDEX NAME)




RN 867018-24-4 CAPLUS  
CN Acetamide, N-[4-[(3-bromo-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2005:570892 Document No. 143:973390 Preparation of pyrrolopyridinyloxyphenylamides and related compounds as cardiovascular agents. . Bennabi, Samir; Heckroth, Heike; Schirok, Hartmut; Mittendorf, Joachim; Kast, Raimund; Stasch, Johannes-Peter; Gnoth, Mark Jean; Muentzer, Klaus; Lang, Dieter; Perez, Santiago Figueroa; Bauser, Marcus; Feurer, Achim; Ehnke, Heimo (Bayer Healthcare A.-G., Germany). PCT Int. Appl. WO 2005058891 A1 20050630, 92 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2. APPLICATION: WO 2004-EP13430 20041126. PRIORITY: DE 2003-10357510 20031209.  
GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. [I; A = Q1, Q2, Q3; R7 = H, halo, cyano, (substituted) alkyl, cycloalkyl, Ph, heteroaryl; Y = O, NH; R1, R2 = H, halo, cyano, alkyl; R3, R4 = H, F, Cl, Me; R5 = H, alkyl; R6 = dimethylaminoethylamino, substituted alkyl, (substituted) alkoxy, cycloalkyl, aryl, heteroaryl], were prepared Thus, title compound (II) (general preparation given) inhibited Rho kinase II with IC50 = 12 nM.  
IT 855862-32-7P 855862-34-9P 855862-36-1P  
855862-38-3P 855862-40-7P 855862-42-9P  
855862-44-1P 855862-46-3P 855862-48-5P  
855862-50-9P 855862-52-1P 855862-54-3P  
855862-56-5P 855862-58-7P 855862-60-1P  
855862-62-3P 855862-64-5P 855862-66-7P  
855862-68-9P 855862-70-3P 855862-72-5P  
855862-74-7P 855862-76-9P 855862-78-1P  
855862-81-6P 855862-83-8P 855862-85-0P  
855862-87-2P 855862-89-4P 855862-91-8P  
855862-93-0P 855862-95-2P 855862-97-4P  
855862-99-6P 855863-01-3P 855863-03-5P  
855863-05-7P 855863-07-9P 855863-09-1P  
855863-11-5P 855863-13-7P 855863-15-9P  
855863-17-1P 855863-19-3P 855863-21-7P  
855863-23-9P 855863-25-1P 855863-27-3P  
855863-29-5P 855863-31-9P 855863-33-1P  
855863-35-3P 855863-37-5P  
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrrolopyridinyloxyphenylamides and related compds. as cardiovascular agents)  
RN 855862-32-7 CAPLUS  
CN 4-Pyridinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)


L4 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855862-34-9 CAPLUS  
CN 1H-Pyrrole-2-carboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 855862-36-1 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-(methylthio)- (CA INDEX NAME)

10582184.trn

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855862-38-3 CAPLUS  
CN Acetamide, 2-(acetylamino)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)



RN 855862-40-7 CAPLUS  
CN Benamide,  
3-cyano-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
(CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 855862-46-3 CAPLUS  
CN Benzeneacetamide,  
N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-  
(CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855862-42-9 CAPLUS  
CN Benamide, 5-chloro-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-methoxy- (CA INDEX NAME)




RN 855862-44-1 CAPLUS  
CN Benzoic acid, 4-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855862-48-5 CAPLUS  
CN Benzeneacetamide, 4-chloro-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A







10582184.trn

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 855862-50-9 CAPLUS  
CN 3-Thiophenecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 855862-52-1 CAPLUS  
CN 2-Thiophenecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-methyl- (CA INDEX NAME)




RN 855862-54-3 CAPLUS

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
CN 2-Thiophenecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-5-methyl- (CA INDEX NAME)




RN 855862-56-5 CAPLUS  
CN Propanoic acid, 3-[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-3-oxo-, methyl ester (CA INDEX NAME)




RN 855862-58-7 CAPLUS  
CN 2-Pyrrolidinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-5-oxo-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855862-60-1 CAPLUS  
CN Benzamide, 4-[[1,1-dimethylethylamino]methyl]-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 855862-62-3 CAPLUS  
CN Acetamide, 2-[[1,1-dimethylethylamino]methyl]-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855862-64-5 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-(propylamino)- (CA INDEX NAME)




RN 855862-66-7 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-[(1-methylethylamino)- (CA INDEX NAME)

10582184.trn

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855862-68-9 CAPLUS  
CN 1-Piperidineacetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 855862-70-3 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-[(trans-4-hydroxycyclohexyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855862-76-9 CAPLUS  
CN Acetamide, 2-[(1,1-dimethylethyl)amino]-N-[3-fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 855862-78-1 CAPLUS  
CN Propanamide, 2-[(1,1-dimethylethyl)amino]-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



● HCl


RN 855862-72-5 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-[(2-hydroxy-1,1-dimethylethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 855862-74-7 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-[(2-hydroxyethyl)amino]- (CA INDEX NAME)


L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 855862-81-6 CAPLUS  
CN Cyclopentanecarboxamide, 3-amino-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 855862-80-5  
CMF C19 H19 F N4 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2

10582184.trn

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855862-83-8 CAPLUS  
CN 2-Piperidinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 855862-85-0 CAPLUS  
CN Cyclopentanecarboxamide, 3-amino-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855862-87-2 CAPLUS  
CN Pentanamide, 2-amino-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-4-methyl-, hydrochloride (1:1) (CA INDEX NAME)




RN 855862-89-4 CAPLUS  
CN 2-Piperidinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855862-91-8 CAPLUS  
CN 4-Piperidinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




RN 855862-93-0 CAPLUS  
CN Acetamide, 2-amino-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855862-95-2 CAPLUS  
CN Propanamide, 2-amino-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 855862-97-4 CAPLUS  
CN Propanamide, 2-amino-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)


10582184.trn

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●x HCl

RN 855862-99-6 CAPLUS  
CN Propanamide, 3-amino-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




●x HCl

RN 855863-01-3 CAPLUS  
CN 2-Pyrrolidinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-4-(phenylmethoxy)-, hydrochloride (1:1), (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 855863-07-9 CAPLUS  
CN 2-Pyrrolidinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-4-hydroxy-, hydrochloride (1:1), (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 855863-09-1 CAPLUS  
CN 1-Piperazinecarboxamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-4-methyl- (CA INDEX NAME)


L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



●x HCl

RN 855863-03-5 CAPLUS  
CN Propanamide, 2-amino-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-hydroxy-, hydrochloride (1:1), (2S)- (CA INDEX NAME)


Absolute stereochemistry.




●x HCl

RN 855863-05-7 CAPLUS  
CN Benzamide, 2-amino-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855863-11-5 CAPLUS  
CN Urea, N-[2-(dimethylamino)ethyl]-N'-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




RN 855863-13-7 CAPLUS  
CN Carbamic acid, [3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)

10582184.trn

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855863-15-9 CAPLUS  
CN Carbamic acid, [3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 3-pyrrolidinyl ester (9CI) (CA INDEX NAME)




RN 855863-17-1 CAPLUS  
CN Carbamic acid, [3-fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855863-23-9 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-[(3-phenylpropyl)amino]- (CA INDEX NAME)




RN 855863-25-1 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-[(3-methoxy-2-(methoxymethyl)-2-methylpropyl)amino]- (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855863-19-3 CAPLUS  
CN Carbamic acid, [3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 855863-21-7 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-[(2-phenylethyl)amino]- (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 855863-27-3 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-[[1(R)-1-(hydroxymethyl)-2-methylpropyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 855863-29-5 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-[(3-methoxypropyl)amino]- (CA INDEX NAME)

10582184.trn

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855863-31-9 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-[methyl(phenylmethyl)amino]- (CA INDEX NAME)




RN 855863-33-1 CAPLUS  
CN Acetamide, 2-[[2-(dimethylamino)ethyl]methylamino]-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855863-35-3 CAPLUS  
CN Acetamide, N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-[(2-methoxyethyl)methylamino]- (CA INDEX NAME)




RN 855863-37-5 CAPLUS  
CN Carbamic acid, [4-[(3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




IT 855863-41-1P 855863-43-3P 855863-45-5P  
855863-49-9P 855863-51-3P 855863-53-5P  
855863-55-7P 855863-57-9P 855863-59-1P  
855863-61-5P 855863-63-7P 855863-65-9P  
855863-67-1P 855863-69-3P 855863-71-7P  
855863-73-9P 855863-75-1P 855863-77-3P  
855863-79-5P 855863-81-9P 855863-85-3P  
855863-87-5P 855863-91-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyrrolopyridinyloxyphenylamides and related compds. as cardiovascular agents)  
RN 855863-41-1 CAPLUS  
CN Acetamide, N-[3-fluoro-4-[[1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)




RN 855863-43-3 CAPLUS  
CN Acetamide, N-[4-[[3-bromo-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]-3-fluorophenyl]- (CA INDEX NAME)


L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 855863-45-5 CAPLUS  
CN Acetamide, N-[3-fluoro-4-[[3-methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]- (CA INDEX NAME)



RN 855863-49-9 CAPLUS  
CN Acetamide, 2-chloro-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)




10582184.trn

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


RN 855863-51-3 CAPLUS

Acetamide, 2-chloro-N-[3-fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)



RN 855863-53-5 CAPLUS


Propanamide, 2-bromo-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl)- (CA INDEX NAME)



RN 855863-55-7 CAPLUS


CN Benzamide, 4-(chloromethyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
 yloxy)phenyl]- (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 855863-61-5 CAPLUS


Carbamic acid, [1-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]-3-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 855863-63-7 CAPLUS


1-Piperidinecarboxylic acid, 2-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 855863-57-9 CAPLUS


CN Carbamic acid, [3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-,  
phenyl ester (9CI) (CA INDEX NAME)



RN 855863-59-1 CAPIUS

Carbamic acid, [3-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-  
yloxy)phenyl]amino]carbonyl]cyclopentyl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)


L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 855863-65-9 CAPLUS

1-Piperidinecarboxylic acid, 4-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


PAGE 1-A




10582184.trn

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 2-A




RN 855863-67-1 CAPLUS  
CN Carbamic acid, [2-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 855863-69-3 CAPLUS  
CN Carbamic acid, [2-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855863-71-7 CAPLUS  
CN Carbamic acid, [2-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 855863-73-9 CAPLUS  
CN Carbamic acid, [3-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855863-75-1 CAPLUS  
CN Benzanide,  
N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-nitro- (CA INDEX NAME)



RN 855863-77-3 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid,  
2-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]-4-(phenylmethoxy)-, 1,1-dimethylethyl ester, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 855863-79-5 CAPLUS  
CN Carbamic acid, [(1S)-1-[(1,1-dimethylethoxy)methyl]-2-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 855863-81-9 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid,  
3-[[[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]amino]carbonyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




10582184.trn

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 855863-85-3 CAPLUS  
CN Acetamide, N-[3,5-difluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-2,2,2-trifluoro- (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 855863-87-5 CAPLUS  
CN Acetamide, N-[4-((3-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy)-3,5-difluorophenyl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 855863-91-1 CAPLUS  
CN Acetamide, N-[3-fluoro-4-((1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl)-2,2,2-trifluoroethyl]-2,2,2-trifluoroethyl- (CA INDEX NAME)

L4 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



L4 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN  
2001:935602 Document No. 136:697410 Preparation of azaindoles as antitumor agents. Longo, Antonio; Brasca, Maria Gabriella; Orsini, Paolo; Traquandi, Gabriella; Pittala, Valeria; Vulpetti, Anna; Varasi, Mario; Pevarello, Paolo (Pharmacia & Upjohn S.p.A., Italy). PCT Int. Appl. WO 2001098299 A1 20011227, 150 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIKX2. APPLICATION: WO 2001-EP6890 20010613. PRIORITY: US 2000-597274 20000619.


GI




AB The title 1H-pyrrolo[2,3-b]pyridines [I; R = H, halo, CN, etc.; R1 = H, alkyl; R2 = alkyl, aryl; R3 = H, CONR4R5, CO2R4, CONHR4, SO2NHR4, alkylsulfonylaminocarbonyl, perfluorinated alkylsulfonylaminocarbonyl; R4, R5 = H, alkyl, aryl, etc.] or their pharmaceutically acceptable salts, useful for treating cell proliferative disorders associated with an altered cell cycle dependent kinase activity (no data given), were prepared Thus, reacting phenylacetic acid with 1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde in the presence of Ac2O and Et3N afforded 44% I [R, R1 = H; R2 = Ph; R3 = CO2H].  
IT 383869-30-5P 383870-18-6P 383871-65-6P  
383872-20-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of azaindoles as antitumor agents)  
RN 383869-30-5 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -[[[4-(aminocarbonyl)phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]- (CA INDEX NAME)

10582184.trn


L4 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 383870-18-6 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -[[4-[[4-(aminocarbonyl)phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]- (CA INDEX NAME)




RN 383871-65-6 CAPLUS  
CN Benzeneacetic acid,  $\alpha$ -[[6-[[4-(aminocarbonyl)phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]- (CA INDEX NAME)



RN 383872-20-6 CAPLUS  
CN Benzeneacetic acid,  $\alpha$ -[[4-[[4-(aminocarbonyl)phenyl]amino]-1H-pyrrolo[2,3-b]pyridin-3-yl]methylene]- (CA INDEX NAME)


L4 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



10582184.trn

=>

Uploading C:\Program Files\Stnexp\Queries\10582184-5.str



chain nodes :  
10 11 13 16 20 21  
ring nodes :  
1 2 3 4 5 6 7 8 9  
ring/chain nodes :  
12 14 15  
chain bonds :  
10-11 11-12 13-14 13-15 16-20 16-21  
ring bonds :  
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9  
exact/norm bonds :  
2-7 3-9 8-9 10-11 11-12 13-14 13-15 16-20 16-21  
exact bonds :  
7-8  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6

G1:[\*1],[\*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 20:CLASS 21:CLASS  
22:Atom

Generic attributes :

16:

Saturation : Unsaturated

10582184.trn




Type of Ring System : Monocyclic

L5 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 [01],[02]




Structure attributes must be viewed using STN Express query preparation.

=> d 15

L5 HAS NO ANSWERS

L5 STR

10582184.trn



G1 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s 15

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 11:02:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 21063 TO ITERATE

100.0% PROCESSED 21063 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 412568 TO 429952

PROJECTED ANSWERS: 1 TO 80

10582184.trn

L6 1 SEA SSS SAM L5

L7 1 L6

=> file reg  
FILE 'REGISTRY' ENTERED AT 11:02:33 ON 27 SEP 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 SEP 2010 HIGHEST RN 1242846-81-6  
DICTIONARY FILE UPDATES: 26 SEP 2010 HIGHEST RN 1242846-81-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s 15  
SAMPLE SEARCH INITIATED 11:02:36 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 21063 TO ITERATE

100.0% PROCESSED 21063 ITERATIONS 1 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 412568 TO 429952  
PROJECTED ANSWERS: 1 TO 80

L8 1 SEA SSS SAM L5

=> s 15 full  
FULL SEARCH INITIATED 11:02:40 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 422397 TO ITERATE

100.0% PROCESSED 422397 ITERATIONS 2 ANSWERS  
SEARCH TIME: 00.00.02

L9 2 SEA SSS FUL L5

10582184.trn

=> file caplus

FILE 'CAPLUS' ENTERED AT 11:02:45 ON 27 SEP 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Sep 2010 VOL 153 ISS 14  
FILE LAST UPDATED: 26 Sep 2010 (20100926/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 19  
L10 1 L9

=> d cbiba bs hitstr 1-  
'CBIBA' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'  
'BS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
CLASS ----- IPC, NCL, ECLA, FTERM  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications  
MAX ----- ALL, plus Patent FAM, RE

10582184.trn

PATS ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)  
STD ----- BIB, CLASS  
  
IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels  
IBIB ----- BIB, indented with text labels  
IMAX ----- MAX, indented with text labels  
ISTD ----- STD, indented with text labels  
  
OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OBIB, indented with text labels  
  
SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations  
  
HIT ----- Fields containing hit terms  
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
containing hit terms  
HITRN ----- HIT RN and its text modification  
HITSTR ----- HIT RN, its text modification, its CA index name, and  
its structure diagram  
HITSEQ ----- HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
its structure diagram  
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
KWIC ----- Hit term plus 20 words on either side  
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.



All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
ENTER DISPLAY FORMAT (BIB):end

=> d cbib abs hitstr 1-  
YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y



10582184.trn

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN  
2006:469591 Document No. 144:4885170 Preparation of 6-substituted  
2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indole derivatives and  
their compositions as protein kinase inhibitors. Wan, Yongqin; Mi, Yuan;  
Fan, Yi; Cheng, Dai; Liu, Yi; Gray, Nathanael Schiander; Albaugh, Pamela  
A. (Irm LLC, Bermuda). PCT Int. Appl. WO 2006052936 A2 20060518, 108 pp.  
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,  
BY,  
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,  
GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG,  
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA; RW: AT, BE, BF,  
BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT,  
LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN:  
PIXXD2. APPLICATION: WO 2005-US40372 20051107. PRIORITY: US  
2004-626785P  
20041109; US 2005-709648P 20050819.  
GI




AB The invention is related to compds. I [U, V, W = independently CR5 and  
derivs., N; R5 = H, alkyl; Q = NR5, NNR5, NO, CR5; L1 = NR5CO, NR5CONR5,  
CONR5, NR5, etc.; L2 = a bond, O, NR5CO, NR5CONR5, CONR5, NR5; n = 0-1; m  
= 0-4; R1 = (un)substituted heteroaryl, hetero/cycloalkyl; R2 = halo,  
NH2, NO2, CN, alkyl, alkoxy, etc.; R3 = H, alkyl; R4 = XR6, XNR5XR6,

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
XOXR6, XNR5XNR5R6; each X = independently a bond, alkylene; R6 =  
(un)substituted heteroaryl, hetero/cycloalkyl, and their  
pharmaceutically acceptable salts, hydrates, solvates, and isomers,  
useful  
for treating or preventing diseases or disorders assocd. with abnormal or  
deregulated kinase activity, particularly diseases or disorders that  
involve abnormal activation of the Abl, Bcr-Abl, cSrc, TPR-Met, Tie2,  
MET,  
FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR,  
PKB,  
PKC, Raf, ROCK-II, Rsk1, SGK, TrkA, TrkB and TrkC kinases were prepd. and  
disclosed. E.g., a multi-step synthesis of indolone II, starting from  
4-fluoro-3-nitroaniline and 3-nitrophenylboronic acid, was given. II had  
an IC50 of 14 nM, 15 nM, 116 nM and 53 nM for TrkB, Aurora-A, c-Raf and  
c-Src, resp. Pharmaceutical compns. comprising compds. I are disclosed.  
IT 887399-18-0P, N-[4-[(4-Methylpiperazin-1-yl)methyl]-3-

trifluoromethylphenyl]-3-[[2-oxo-3-[(1H-pyrrol-2-yl)methylene]-2,3-dihydro-  
1H-pyrrolo[2,3-b]pyridin-6-yl]amino]benzamide 887399-21-5P,  
3-[[2-Oxo-3-[(1H-pyrrol-2-yl)methylene]-2,3-dihydro-1H-pyrrolo[2,3-  
b]pyridin-6-yl]oxy]-N-(3-trifluoromethylphenyl)benzamide  
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(drug candidate; preparation of 2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-  
dihydro-1H-indole derivs. as protein kinase inhibitors)  
RN 887399-18-0 CAPLUS  
CN Benzamide, 3-[[2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-  
pyrrolo[2,3-b]pyridin-6-yl]amino]-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-  
(trifluoromethyl)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)  
RN 887399-21-5 CAPLUS  
CN Benzamide, 3-[[2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-  
pyrrolo[2,3-b]pyridin-6-yl]oxy]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX  
NAME)



10582184.trn

=> FIL STNGUIDE

FILE 'STNGUIDE' ENTERED AT 11:15:31 ON 27 SEP 2010  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Sep 17, 2010 (20100917/UP).

=>